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Abstract 
Asthma is characterized by variable airway obstruction, airway 
hyper-responsiveness and influx of inflammatory cells such as eosinophils into the 
bronchial mucosa. Recent studies have highlighted the relationship between airway 
inflammation, airway hyper-responsiveness and the management of childhood asthma. 
Examination of cellularity in the airways by means of broncho-alveolar lavage or 
bronchial biopsy is the direct method in assessing airway inflammation. However, 
their use in paediatric clinical practice is limited because of their invasive nature. 
Hypertonic saline challenge and sputum induction (HSCSI) has established itself as 
an easy and reliable method that is able to assess airway inflammation and airway 
hyper-responsiveness during the same procedure. Examination of the cellular 
components in sputum could indirectly reflect the inflammatory status of the 
underlying airways. 
In this thesis, studies utilizing HSCSI were carried out to (1) evaluate the factors 
that predict successful sputum induction in children, (2) evaluate the effectiveness of 
once-daily fluticasone propionate in children with stable asthma by studying the 
control of airway inflammation and (3) examine the relationship between cough 
frequency and airway inflammation in children with stable asthma 
. I n the study of successful sputum induction in children, 130 subjects were 
iv 
Abstract - English Version 
recruited. The median age was 11.25 years (IR: 5) and majority were boys (75%). All 
except two had normal percent predicted FEVi (> 80%). Sputum induction was 
successful in 93 subjects (74.5%). Sore throat and chest discomfort occurred in 20 
(15%) and 8 (6%) subjects respectively and the procedure was prematurely terminated 
in three cases. Exhaled nitric oxide (eNO) was found to be a significant predictor for 
successful induction. (Area under ROC curve - 0.634). 
In the second study, we were able to show that once-daily fluticasone proprionate 
were as effective as the twice-daily regimen in controlling airway inflammation. 
There were, in fact, significant improvements in eNO and sputum eosinophil counts 
when the corticosteroids therapy was changed from twice-daily to once-daily. In 
addition, all subjects preferred the once-daily dosing regimen. 
We used a validated cough monitor to assess cough frequency in children with 
mild asthma. They were found to have greater cough frequency compared to normal 
children - 25.5 (IQR 16 - 42.8) versus (11 episodes per day, p<0.001). Cough 
frequency was found to have a significant positive correlation with sputum neutrophil 
count (r=0.833, p=0.0001)，suggesting that the increased cough may be driven by a 
neutrophilic pathway. 
In conclusion, HSCSI is safe and well tolerated among children. It has its clinical 
value as a non-invasive assessment tool of airway inflammation. 
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個患兒參與(男 :75%人；女: 2 5%)，年齢中位數為11 .25歲（ IR:5)�所有患兒都有 
正常基礎FEVi(> 8 0 % ) �e N O 中位數為 4 8 . 9 5 p p b . �的硏究結果顯示，誘導痰 
成功的患 f a人數為 9 3人 ( 7 4 . 5 % ) �有喉嘴不適徵狀的有 2 0人，有胸口不適徵狀 
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的有8人（6%)，未能完成激發試驗的有3人。eNO是哮喘患兒成功通過高滲鹽 





度的哮喘患兒之F E V i中位數及 e N O中位數分別為 8 3 . 3 % (IQR 81.1-97.6)及 
56.1 ppb (IQR 37.4-105)o咳嗽頻率中位數為25.5 (IQR 16~42.8)與正常兒童之咳 
嗽頻率 ( l l ,p<0.001)有統計上重要的分別。有69%患兒成功誘導痰液，而咳嗽頻 
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Chapter 1 Objectives of studies 
Chapter 1 Objectives of studies 
The primary objective of the study was to implement the technique of 
hypertonic saline challenge with sputum induction (HSCSl) for use in 
paediatric patients at Prince of Wales Hospital. We then examined the safety 
and success rate of HSCSI in Hong Kong Chinese children with asthma. 
The technique was then used to (1) study the relationship between airway 
inflammation and cough frequency in children with mild asthma, (2) assess 
whether the use of inhaled corticosteroids on an once-daily basis was as 
effective as the traditional well accepted twice-daily regimen, using airway 
inflammation as our outcome measure. In each study, we used the technique of 
HSCSI to obtain sputum samples for the assessment of differential cell counts 
which served as a marker of airway inflammation. We also attempted to find 
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2.1 Definition of asthma 
The term "Asthma" is derived from the Greek word meaning panting. 
It has been known and described for more than 2,000 years. It is the 
commonest chronic childhood disease in many areas in the world, including 
Hong Kong. (Kaur B et a l , 1998) Since many different mechanisms and 
causal pathways are involved in the development of asthma, an exact 
definition of asthma is seldom defined. However, investigators have devised 
several working definitions of asthma for epidemiological and research 
purposes. 
Clinical Definition 
Asthma is an inflammatory disease of the airways that is associated 
with abnormal response mechanisms of the airway smooth muscles that lead 
to episodes of airway narrowing. (Woolcock AJ, 1994) 
Pathological Definition 
Asthma is a disease of the airways characterized by chronic 
• inflammation with infiltration of lymphocytes, eosinophils and mast cells 
together with epithelial desquamation, thickening, and disorganization of 
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American Thoracic Society Definition 
Asthma is a clinical syndrome characterized by increased 
responsiveness of the tracheobronchial tree to a variety of stimuli. The 
major symptoms of asthma are paroxysms of dyspnoea, wheezing and 
cough, which may vary from almost undetectable to mild to severe and 
unremitting. The primary physiological manifestation of this 
hyper-responsiveness is variable airways obstruction. This can take the form 
of spontaneous fluctuations in the severity of obstruction following 
bronchodilators or corticosteroids, or increased obstruction caused by drugs 
or other stimuli. (American Thoracic Society, 1987) 
In the most recent United State asthma guideline, the Expert Panel 2 
Report defines asthma as: 
‘‘A chronic inflammatory disorder of the airways in which many cells 
and cellular elements play a role, in particular, mast cells, eosinophils, T 
lymphocytes, neutrophils, and epithelial cells. In susceptible individuals, 
this inflammation causes recurrent episodes of wheezing, breathlessness, 
chest tightness, and cough, particularly at night and in the early morning. 
These episodes are usually associated with widespread but variable airflow 
obstruction that is often reversible either spontaneously or with treatment. 
This inflammation also causes an associated increase in the existing 
bronchial hyper-responsiveness to a variety of stimuli." (National Asthma 
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The definition of asthma highlights the importance of exacerbations as 
a feature of asthma, and emphasizes the fluctuations of the disease. 
Normally, asthma episodes are referred to as "acute attacks" if they are 
short-lived and easily reversed with reliever medications. However, if the 
acute symptom episode lasts longer than one day, the attack is referred to as 
an "asthma exacerbation". 
Definitions for asthma have limitations since they can reflect only 
current understanding of the diseases, which is quite limited. In addition, 
clinical symptoms of asthma overlap with other respiratory diseases making 
a clear distinction difficult. For children, similar symptoms may present 
with bronchiolitis and wheezy bronchitis, for elderly, chronic bronchitis and 
emphysema. Asthma will continue to be redefined as our understanding of 
the condition deepens, and as new effective preventive strategies and 
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2.2 Diagnosis and classification of asthma in children 
The diagnosis of asthma in children often relies heavily on clinical 
history since many children are too young to do the tests that objectively 
measure airflow obstruction. Several studies have called attention to 
significant under-diagnosis and under-treatment of childhood asthma. 
(Speigth ANP et a l , 1983; Clifford RD et al., 1989; Kirshner B et al., 1990) 
By school-age, children are able to perform simple spirometry and the 
diagnosis can be supported with more formal evaluation. Therefore, the 
school-age children who are able to perform spirometry and peak flow 
measurements are the target for the diagnostic criteria and assessment 
method suggested in this chapter. 
There are two main types of guidelines in classifying asthma severity -
the National Institutes of Health Global Initiative for Asthma (GINA) 
guidelines (National Asthma Education and Prevention Program Expert 
Panel Report 2, 1997) classify asthma severity based on symptoms and the 
British Thoracic Society (BTS) guidelines classify (The British Thoracic 
Society and others, 1997) asthma severity based on the medication needed 
• to control symptoms. However, it is often difficult to apply either system in 
real life, as many a time's patients are still symptomatic while on treatment 
and they cannot simply be classified into one or the other system. A general 
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Mild asthma: Discrete attacks for no more than 1 — 2 days occurring no 
more often than once per month with symptom-free intervals or very brief 
attacks occur no more than twice per week. This group corresponds 
approximately to GINA steps 1 - 2, BTS step 1. 
Moderate asthma: Attacks more often than twice weekly with 
occasional more prolonged exacerbations and some nocturnal symptoms. 
This group corresponds approximately to GINA steps 2 - 3 , BTS step 2 - 3 . 
Severe asthma: Continuous or virtually continuous symptoms by day 
and some nocturnal disturbance with occasional prolonged severe 
exacerbations. This group corresponds approximately to GINA steps 3 - 4 , 
BTS step 3 - 5 . 
Mild and moderate asthma may well be seasonal with complete or 
virtually complete symptoms free intervals once the relevant season is over. 
Severe asthma is rarely seasonal although the severity of symptoms (and 
need for treatment) may fluctuate from time to time. 
Whatever the overall pattern of asthma takes in a particular individual 
patient, the severity and frequency of attacks vary from time to time. It is 
important to note that there is no direct link between the overall severity of 
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2.3 Assessment of asthma in school-age children 
Childhood asthma is a disease that causes much mortality and 
morbidity (Campbell MJ et a l , 1997; Janson C et al., 1997; Dente FL et al.， 
2004), and emphasis has been given for the close monitoring of one's 
asthma status. Monitoring the patient's symptoms is the focus of asthma 
assessment. However, symptom monitoring is subjective and liable to recall 
bias. In clinical practice, supportive evidence provided by more objective 
measurements such as spirometry, peak flow expiratory rate (PFER), 
non-invasive airway inflammatory assessments, such as exhaled nitric oxide 
measurement and hypertonic saline challenges and induced sputum is often 
required. 
2.3.1 Clinical History 
Symptoms associated with asthma include wheeze, dyspnoea, cough 
and nocturnal waking. For school age children, the diagnosis of asthma is 
likely given a characteristic history of recurrent wheeze, shortness of breath 
and cough, or even recurrent cough by itself. An asthmatic child often has a 
history of cough and / or wheeze with viral illness. Symptoms induced by 
. exercises are also suggestive of an underlying hyperactive airway. There 
may also be symptoms occurring between respiratory tract infections at 
night or in the morning on arising and many a times the child would become 
symptomatic with weather change. However, it is worth noting that clinical 
history and symptom rely on accurate patient reporting and are difficult to 
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2.3.2 Atopy 
A child with atopy produces specific IgE antibodies after exposure to 
common environmental allergens and is said to be sensitised to that allergen. 
The presence of specific IgE antibodies is measured by means of a skin 
prick test or radioallergosorbent testing (RAST). (Gold MS & Kemp AS, 
2005) Allergens were considered as important for the development of 
asthma but it is reported that the closeness of the association between atopy 
and asthma remains unknown. (Platts-Mills TA & Chapman MD, 1987) 
Many individuals who develop asthma in later life and a minority of 
younger patients fail to show any obvious signs of allergy. On the other 
hand, whether a non-allergic asthmatic state actually exists has been 
questioned (Burrows B et al.，1989) 
During the last 10 years, there has been substantial effort devoted to 
genetic studies of asthma and allergic diseases on the basis of candidate 
gene approaches and genome-wide linkage studies in human and animal 
models. Up to now, despite significant findings regarding susceptibility 
regions and genes in some cases, these studies have still resulted in only a 
very limited understanding of asthma and allergic diseases. Some of the 
reasons for the failure to replicate the detection of particular loci across 
studies and for the modest contribution of each of these susceptibility loci 
might relate to heterogeneity factors between studies that might be difficult 
to detect and take into account in small-scale studies. Enlarging the number 
of participants in a given study has thus been proposed to increase the 
, power to detect even small effects. Alternatively, identifying the factor or 
mr： 
factors that conceal the underlying effect and thereby unmask the true 
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relation between genetic susceptibility and development of a certain 
condition will result in a more profound understanding of the primary 
biologic mechanisms, (von Mutius E, 2004) 
Cockroach has been identified as an important source of indoor 
allergens. The major cockroach allergens are Bla gl and Bla g2. The 
presence of cockroach debris in house dust has been shown for a long time. 
Cockroach infestation is highest in crowded urban areas. It was reported 
that the increased asthma morbidity and mortality rates in inner cities could 
be related in part to cockroach allergen exposure (Sarpong SB et al., 1996) 
In a group of 87 children aged 5 to 17 years with moderate to severe allergic 
asthma, over 80% of children with bedroom major cockroach allergens (Bla 
gl and Bla g2) of 1 U/gm or greater demonstrated skin sensitivity to . 
cockroach allergen. The results has confirmed the high prevalence of 
sensitization to cockroaches and emphasized the frequency of combined 
sensitization to house dust mites. 
Pollen from wind-pollinated plants such as grass, trees and weeds can 
. trigger both asthma and hayfever. In a study of 5,427 subjects with age of 
18 to 65-year-old, prevalence of hay fever symptoms together with a 
positive skin test to pollen was significantly higher in the exposed (13.6%) 
vs less exposed community (5.5%) (Charpin D et al., 1993) In contrast, 
prevalence of asthma with positive skin test was 2.5% and 1.9% 
respectively. The study, therefore, concluded that high exposure to pollen is 
, a risk factor for developing hay fever but not asthma. 
9 
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Fungal spores can be found in moist areas such as basements, food 
storage areas, and waste receptacles; however its triggering power is less 
than pollen. (Solomon WR et al., 1978) 
Household animals especially dogs and cats may release allergen 
through saliva in hairs. It was reported that that the prevalence rate for 
asthma in children with animals was twice that of children without animals. 
(Abdulrazzaq YM et al., 1995) 
^ ^ • . • • 5 
“ ‘ iiMii 
Fig. 2.1: Skin prick test (SKT). A child was considered atopic if he had at 
least one skin test result that showed an induration with a diameter of at 
least 2 mm greater than the negative (normal saline) control. 
2.3.3 Lung Function Test 
Spirometry and peak flow measurement are useful for the management 
of asthma. The most common and clinically applicable indices are Forced 
Expiratory Flow at 1 second (FEVi), i.e. the maximum volume of air 
expired in the first second from full inspiration; and Peak Flow Expiratory 
Rate (PEFR), i.e. the highest flow obtained during a forced expiration 
starting immediate after a deep inspiration at total lung capacity. The degree 
of reduction of FEVi is used to define the severity of obstruction. Serial 
‘ measurements of FEVi and PEFR are taken in the follow-up of patients to 
10 
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assess the degree of asthma control. These measurements together with self 
reported symptoms are then utilized to make therapeutic decisions. 
All measurable parameters of pulmonary function may be within 
normal limits when the patient with asthma is in remission. Typical 
abnormalities noted with spirometry in an asthmatic patient include a 
reduction in FEVi, PEFR, FEVi/FVC ratio, and an increase of 15% or 
greater in FEVi in response to a bronchodilator. (National Asthma 
Education and Prevention Program Expert Panel Report 2, 1997) Excessive 
variability in home peak flow monitoring, either a diurnal variation of 20% 
or more, or day to day variation of 20% or more, or a 20% response to 
bronchodilator, would help to confirm the diagnosis of asthma. (Woolcock 
AJ et al.，2001) Abnormalities in lung volumes include a decreased vital 
capacity, an increase in functional residual capacity, total lung capacity, and 
especially in the residual volume are other characteristics of asthma. 
Spirometry with flow-volume loops may provide additional 
information for diagnostic purposes or when assessing the degree of 
severity of asthma. (Linna OV, 1993) In particular, the maximum expiratory 
flows from the flow-volume loop are more sensitive to lesser degrees of 
airway obstructions. (Landau LI, 1993) However, spirometry is only 
practical in children who can perform a forced vital capacity maneuver, 
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m 
mK^L 
Fig. 2.2 Spirometry 
It should be emphasized that the diagnosis of asthma does not rely 
purely on lung function measurements. (National Asthma Education and 
Prevention Program Expert Panel Report 2, 1997) Normal expiratory flows 
do not exclude the diagnosis of asthma because asthma often causes only 
episodic airway narrowing and signs and symptoms are not always present. 
Reduced expiratory flow, which improves significantly after inhaled 
bronchodilator, is also present in other pulmonary disorders, such as 
obstructive bronchitis, or normal subjects following viral upper respiratory 
. infection. 
The use of FEVi / PEFR is associated with a variety of limitations: 
• Expiratory maneuver is effort dependent, and proper training is 
required to obtain the best and most reproducible measurements 
from the individual. (Frischer T et a l , 1995) 
. • PEFR mainly reflects the calibre of large airways and 
under-estimate the degree of airflow limitation present in 
12 
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peripheral airways. Therefore, single measurement of PEFR is not 
recommended in making the first diagnosis of bronchial 
obstruction. (Sawyer G et al., 1998) 
• Although predicted values of PEFR related to gender, race, age 
and height are available in the literature, (Reddel HK et al., 1998) 
however, the inter-individual variability is wide and some subjects 
have PEFR values that are different from the average value of 
subjects with the same demographic characteristics. 
• Some subjects with long-lasting asthma may develop irreversible 
airflow limitation. Therefore, nowadays, it is more useful to 
establish the best personal PEFR observed during a period of 
effective treatment to obtain reference values to use in the 
assessment of long- term changes. (Reddel HK et al., 2004) 
• It has been suggested that post-bronchodilator FEVi or 
FEVi/FVC ratio are better indicators of airway pathology; 
however, FEVi may not give as reliable guide to the degree of 
small airway pathology as FEF25-75. 
It has to be emphasized that a negative test result of spirometry and • 
PEFR cannot exclude a diagnosis of asthma, as many well-treated 
asthmatics have normal lung function and simply do not have the capacity 
to increase their FEV, any further. Moreover, the abnormal airway 
physiology is not often present even in cases with severe asthma. (Enright 
PL et a l , 1994; Hunter CJ et al., 2002; Clancy K., 2004) In addition, these 
measures do not correlate closely to the underlying eosinophilic airway 
inflammation, which is a predictor of asthmatic exacerbation and precursor 
13 
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of airway remodeling. (Crimi E et al., 1998) Furthermore, the lack of a gold 
standard and the effort dependent nature of the tests might lead to the risk of 
either over-diagnosis or an under-estimation of asthma. (Britton J & Lewis 
S., 1998; Miller MR et al., 1998; Sawyer G et al., 1998) 
2.3.4 Exhaled Nitric Oxide 
Assessment of exhaled nitric oxide (eNO) is an attractive technique in 
assessing airway inflammation in childhood asthma because of the 
non-invasive nature of the technique, direct and rapid availability of the 
results. 
eNO is generated by isoforms of nitric oxide synthase (NOS; types I -
III) in the airway epithelium and from pulmonary macrophages. 
Constitutive NOS (Type III) is probably responsible for the basal levels of 
eNO seen in normal subjects. When the airways are inflamed, inducible 
NOS (Type II) will be expressed in the epithelium that is responsible for the 
elevated level of eNO. 
In children, eNO levels were positively correlated with the absolute 
level of peripheral blood eosinoiphils (Silvestri M et al., 1999) and sputum 
eosinophils (Grootendorst DC et a l , 1997). Therefore, eNO levels in asthma 
may be related to the eosinophilic inflammation. 
The relationship between eNO and neutrophil in airways is less clear. 
. Studies have shown that eNO is either the same or slightly elevated eNO 
level was demonstrated in a group of cystic fibrosis children with intense 
14 
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neutrophils infiltrate compared with normal children. (Ho LP et al., 1998) 
One possible explanation is that NO is converted to peroxynitrite and nitrate 
by superoxide in activated neutrophils. 
It is reported that eNO levels increased with severity of atopy 
measured by SKT. (Franklin PJ et al., 1999) The result might imply 
subclinical inflammation in individuals. However, viral upper respiratory 
tract infections and influenza vaccination have been associated with 
elevation of eNO in adults. (Kharitonov SA et a l , 1995; Thomas PS et al., 
1999) 
, y Fig. 2.3 Sievers 280i NOA analyzer for 
H ^ measuring eNO 
_ 
The use of eNO measurement in assessing airway inflammation has 
several limitations: 
• There are variations in the methods of collection of samples have 
“been described in literature, including on-line and offline 
measurements. Guidelines with suggestions for collection and 
analysis have been published in Europeans and Amercian 
. literatures (Kharitonov S et a l , 1997; American Thoracic Society, 
一 1999) 
15 I 
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• Lack of universal reference cut off value available for 
distinguishing normal and asthma children. 
• Reported values of eNO in healthy subjects vary from 3 ppb to 88 
ppb. (Kharitonov SA et a;L, 1995; Dotsch J et al., 1996; Scollo M 
et al., 2000; Latzin P et al., 2002; Pijnenburg MW et al., 2002) The 
variations may be caused by different measurement techniques and 
low numbers studied. 
• Confounding factors in measuring eNO such as age, sex, and atopic 
symptoms have not always been taken into account in these studies. 
• Varieties of commercially available eNO machine are costly, bulky 
in size, lack of reference value and inter-machine variation studies, 
which limits its use in clinical setting. (Gutafsson LE et al., 1998) 
2.3.5 Airway Hyper-responsiveness measurement 
Airway hyperresponsiveness (AHR) is an abnormal increase in airflow 
limitation following the exposure to a stimulus. The word "abnormal" refers 
to a comparison with the airway response to the same agonist, using the 
same method to measure the airflow limitation, in a group of healthy 
subjects. The wording "airflow limitation" is used because it encompasses 
the different mechanisms that can lead to a decrease in the parameters of 
airflow (Pauwels R, 1997). Although AHR is not specific for asthma, nearly 
all patients with asthma exhibit increased responsiveness. The severity of 
AHR also predicts the response to inhaled corticosteroids in patients with 
asthma (Juniper EF et a l , 1981) 
4 
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The stimuli have been divided into direct and indirect so as to highlight 
the heterogeneity of the airway response to the different stimuli. (Pauwels R, 
et a l , 1988; Rogers DF & QiConnor BJ, 1993; Sterk PJ et al., 1993) Direct 
challenges with histamine or methacholine have been used by researchers 
since 1940s for assessment of AHR. They can be used to establish a dose 
response and time course of the acute bronchoprotective effects of 
beta-agonists. In addition, they have also been used to assess the potential 
anti-inflammatory effects of prolonged treatment with new agents. However, 
inhaled corticosteroids, the current gold standard anti-inflammatory 
treatment for asthma, reduces AHR to methacholine and histamine to a 
small degree, which is the limitation for the potential use of direct stimuli in 
the evaluation of anti-inflammatory drug. 
The proposed mechanism for the airflow limitation caused by 
methacholine and histamine challenge (direct stimuli) in adult involve the 
direct action on the effector cells, such as airway smooth muscle cells, 
bronchial vascular endothelial cells and mucus producing cells. For indirect 
stimuli such as 4.5% hypertonic saline, it caused airflow limitation by an 
• action on cells other than the effector cells; these cells then interact with 
these effector cells. However, whether the same mechanism will apply to 




Chapter 2 Literature Reviews 
Direct Stimulus Indirect Stimulus 
I i  
Effector cells , ^ „ 
e.g. Airway smooth cells ^ 二ermed:ary ce s 
Bronchial epithelial cells ^ 一 e.g. Inflammatory cells and 
Mucus producing cells neuronal cells  
” 
Airflow limitation 
Fig. 2.4 Direct and indirect stimulus lead to airflow limitation 
(Joos GF et al., 2003) 
In recent years an increasing number of studies have investigated the 
relative usefulness of indirect airway challenges in monitoring 
anti-inflammatory treatment in asthma. The airways of asthmatics, but not 
healthy persons, narrow in response to "indirect" stimuli. For this reason, 
airway inflammation and the number of inflammatory cells such as mast 
cells and eosinophils are likely to be the important determinants of the 
abnormal airway response to these challenges. Treatment with inhaled 
steroids significantly reduces airway responsiveness to indirect stimuli in 
adult studies (Vathenen AS et al., 1991; Anderson SD et al., 1994; Pedersen 
S et al., 1995; du Toit JI et a l , 1997; Doull J et al., 1997; Brannan JD et al., 
2002) and mast cell release of mediators is associated with 
hyper-responsiveness to indirect stimuli. (Polosa R et al., 1995; O'Sullivan 
t 
S et al., 1998) 
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The pattern of indirect stimuli differs from direct stimuli is shown by 
the following evidence. 
• Airway responsiveness to direct and indirect challenges are rather 
poorly correlated with each other (Pauwels et al., 1988) 
• A wide array of mediators including histamine, leukotrienes, 
prostaglandins, acetylcholine, neuropeptides are involved in the airway 
narrowing induced by the indirect stimuli. (Van Schoor J et al., 2000) 
• The airway narrowing caused by an indirect, but not a direct challenge, 
can be prevented by acute pretreatment with a cromone (cromoglycate, 
nedocromil), inhaled frusemide and / or heparin (Van Schoor J et al., 
2000) 
參 In patients with asthma, airway responsiveness to an indirect airway 
challenge is more closely associated with airway inflammation than 
airway responsiveness to a direct stimulus (Van Den Berg G et al., 
2001) 
參 Airway responsiveness to an indirect stimulus may also better reflect 
acute changes in airway inflammation induced by allergen avoidance 
(van Velzen E et a l , 1996) or by treatment with inhaled steroids. 
(Taylor DA et al., 1999; Hofstra WB et al., 2000) 
The major advantage in using indirect stimuli to test for active asthma 
is their capacity to act on many different cells so that a wide variety of 
substances contribute to the narrowing that follows. Late responses after 
these challenges however are rare. (Phillips GD et al., 1990; O'Sullivan S et 
a l , 1998) Another important advantage of challenge with indirect stimuli is » 
the lack of false-positive tests. Healthy subjects respond with mean falls in 
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FEVi of 2 to 6% (Riedler J et al., 1994 & 1998; Hurwitz KM et al., 1995; 
Rabone SJ et al., 1996; Godfrey S et al., 1999), or small change in 
conductance. (Cushley MJ 1983) 
Indirect challenges act by causing the release of endogenous mediators 
that cause the airway smooth muscle to contract, with or without effect in 
inducing micro-vascular leakage. Because the responses to these challenges 
are modified or even completely inhibited by inhaled steroids, the airway 
response to these challenges may be a closer reflection of active airway 
inflammation. They are thus potentially useful in the evaluation of efficacy 
and to monitor the response to treatment. (Jonasson G et a l , 2000). A 
negative response to an indirect challenge suggests that the person either 
does not have asthma or that the asthma is currently under control with 
treatment. 
When the airway response to an indirect stimulus is inhibited after 
regular treatment with steroids, it is unlikely that the inflammatory cells and 
mediators are present in significant numbers or concentration to cause 
airway narrowing. This concept is important because the airways of 
asthmatics generally remain hyper-responsiveness when the agonist is given 
directly to the airways, as it is with a pharmacological challenge. (Vathenen 
AS et al., 1991; Sont JK et al., 1999; Reddel HK et al., 2000) 
I » 
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Fig. 2.5 Hypertonic saline challenge 
2.3.6 Airway inflammation measurement 
Airway inflammation is defined as the presence of activated 
inflammatory cells in the airways. Airway inflammation is a major 
characteristic of childhood asthma that usually has an eosinophilic 
component. Airway inflammation is important in the pathogenesis of 
asthma. Pathophysiologically, as well as accumulation of eosinophils and 
CD4 lymphocytes, there is activation of the epithelium and smooth muscle, 
mucus hypersecretion, thickening of the sub-epithelial collagen layer, mast 
cell degranulation, and smooth hypertrophy and hyperplasia. (Kay AB, 
1996) Therefore, prevention and treatment of airway inflammation is the 
mainstay of asthma management. (Boulet LP, 1999) 
The nature and extent of airway inflammation has been assessed using 
I 
— direct, invasive bronchoscopy with bronchial washings or biopsy or 
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bronchoalveolar lavage (BAL), or by indirect measurements of symptoms, 
spirometry, peak expiratory flow, tests of airway hyper-responsiveness or 
peripheral blood inflammatory markers (Pauwels R，1996) Bronchoscopy 
with examination of cellularity provides the gold standard assessment of 
airway inflammation, which is limited by discomfort to the patient, expense 
and risks of the procedure, especially in school-age children. The indirect 
measurements relate variably with each other and reflect more than airway 
inflammation, for which they are nonspecific. As a result, not surprisingly, 
they may not correlate with direct measurements of airway inflammation. 
(Haley K & Drazen J, 1999) 
Examination of induced sputum has evolved as a direct, relatively 
non-invasive, valid method of measuring airway inflammation over the last 
decade for children. (Pin I et a l , 1992) It has emerged as an important and 
useful technique to study airway inflammation in childhood asthma because 
it is non-invasive and allows sample to be collected on repeated occasions. 
Sputum induction has been used to study asthma in children since the first 
description of the technique by Pin I et al in 1992 (Pin et al., 1992) Sputum 
• is induced by inhalation of isotonic or hypertonic solutions administered by 
nebulisation. The aim of sputum induction is to collect an adequate sample 
of secretions from lower airways in subjects who do not produce sputum 
- and expectorate it spontaneously. 
I 
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In general, sputum induction in children of more than 6 years old is 
safe and has a successful rate varies from 68% - 100%. (Gibson PG et al., 
2002) Sputum induction in younger children is limited by their poor 
spirometric technique and low tidal volume, which limits the dose of saline 
that can be delivered. (Riedler J and CF Robertson, 1994) In most studies, 
the procedure is well tolerated by children and possible side effects reported 
include cough, bronchospasm, vomiting and anxiety. (Pizzichini E et al., 
2002; Covar RA et al., 2004; Rytila P et al., 2004) The procedure is equally 
well tolerated by children with severe asthma and those" with an acute 
exacerbation. (Twaddell SH et al., 1996) 
The proposed mechanism of sputum induction is that during the 
inhalation of isotonic or hypertonic solution, the increased osmolarity of the 
airway lining fluid increases vascular permeability in the bronchial mucosa 
and induces production of mucus by submucosal glands, which has been 
demonstrated in animal studies. (Umeno E et al., 1990) However, in vivo 
instillation of hypertonic solution into the airways of animals and humans 
induces an increase in the levels of several mediators but no rise in levels of 
‘ albumin or other markers of increased vascular permeability. (Gravelyn TR 
et al., 1988; Freed AN et al., 1994) Therefore, the hypothesis has not been 
completely confirmed and only preliminary measurements of sputum 
- osmolarity after induction have been reported with conflicting results. 
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When the induced sputum processed under standardized procedures, 
the results were reproducible. (Fahy JV et al., 1993 & Pizzichini E et al., 
1996) The procedure is well tolerated by children with a success rate up to 
80% (Gibson PG et al., 2000) The inflammatory findings correlate best with 
bronchial washings and more variably with bronchial biopsies and BAL 
because they reflects differences in different airway compartments. (Fahy 
JV et al., 1995; Maestrelli P et al., 1995; Grootendorst DC et a l , 1997; 
Keatings VM et a l , 1997; Pizzichini E et al., 1998) Induced sputum and 
bronchial washings reflect secretions from the more central airway lumen, 
BAL from the peripheral lumen and bronchial biopsies from the more 
central airway walls. In addition, sputum eosinophils are more sensitive and 
specific for the presence of asthma than blood eosinophils or eosinophilic 
cationic protein (ECP) (Pizzichini E et al., 1997) 
The value of using sputum eosinophils as assessment tool in airway 
inflammation has been highlighted in both adult and children studies. 
(Pavord ID et al., 1997; Keatings VM et al., 1996) In selected published 
studies, up to 80% of corticosteroid-naive children (Green RH et al., 2002; 
‘ Pizzichini E et al.，1996; Silkoff PE et a l , 2003) and more than 50% of 
corticosteroid treated children (Pavord ID et al., 1997) with concurrent 
symptoms have sputum eosinophils count outside the normal range. Thus 
the monitoring of sputum eosinophils may allow better asthma control and 
provide a useful guide in management. Recent evidence suggests that a 
treatment strategy directed at normalization of airway eosinophil reduces 
, asthma exacerbations and hospital admissions in children. (Gibson PG et a l , 
‘ 2000) 
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In asthmatic patients, the number of eosinophils is elevated when 
compared with normal controls. There is a correlation between 
measurements of eosinophils counts obtained in induced sputum with BAL 
fluid in adult. (Keatings VM et al., 1997) In addition, there is a correlation 
between the change in airway responsiveness and the change in sputum 
eosinophils count after allergen challenge (Pin I et al., 1992) and sputum 
eosinophils are reduced by steroid treatment in a dose-dependent manner in 
adult. (Gibson PG et a l , 2000) Sputum eosinophils are elevated in some 
patients with severe intractable asthma. (Jatakanon A et al., 1998; Wenzel 
SE et a l , 1997) 
_ 




Chapter 2 Literature Reviews 
Although induced sputum is a direct, relatively non-invasive, valid and 
repeatable method of measuring airway inflammation; sputum examination 
has been traditionally limited by the difficulty in obtaining adequate 
samples, especially in children. The use of 4.5% hypertonic saline to 
facilitate sputum production and dithiothreitol to improve cell dispersion 
has allowed this procedure to be applied successfully. Combined hypertonic 
saline challenges and sputum induction is a non-invasive, safe, cost saving 
and reproducible method in assessing childhood asthma. HSCSI can assess 
airway inflammation and airway hyper-responsiveness at the same time 
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2.4 The use of HSCSI in clinical trial 
2.4.1 Role of sputum eosinophil count in childhood asthma 
The sputum eosinophil plays an important role in the evaluation of 
airway inflammation in childhood asthma. By assessing the degree of 
airway inflammation and targeting treatment in relation to response, we 
could prevent children from being exposed to unnecessarily high dose of 
inhaled corticosteroid and suffer from its potential side effects. In addition, 
asthma frequently begins in childhood and becomes chronic by adulthood; 
therefore, it is necessary to evaluate the role of airway inflammation in 
children in order to study the role of airway inflammation in the genesis of 
asthma. Thus, the greatest clinical application of sputum induction is to 
study the extent of airway inflammation non-invasively in children as the 
use of bronchoscopy or biopsies have been very limited due to ethical and 
safety reasons. (Gibson PG et al., 1998) Induced sputum may further 
provide important insight into the pathology and mechanism of asthma and 
its determinants of severity. Sputum induction allows the analysis of 
mediators such as proteins and cytokines that are present in the fluid phase 
of the sputum sample. (Pin I et al., 1992; Fahy JV et al., 1995; in't Veen JC 
. et a l , 1999; Gibson PG et al., 2000) These mediators in sputum can be 
assessed by ELISA (Enzyme-Linked Immunosorbent Assay) or bioassays 
techniques. However, some components in sputum such as the salivary 
proteins (mucins), degradation products such as DNA and actin released 
from dead cells may interfere with both the quantitative and qualitative 
measurement of cytokine function. (Louis R et al., 1999; Perks B et a l , 
, 2000) A standardized method is not established currently for the proper 
assessment of these fluid-phase mediators. 
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2.4.2 Role of sputum induction in predicting asthma exacerbation 
In a study by Green RH et al., they found that higher level of sputum 
eosinophils correlated with greater airway obstruction and the increase in 
sputum eosinophils can be considered as a predictor for asthma 
exacerbations. (Green RH et al., 2002) Apparent stable asthmatics with high 
eosinophil counts are more likely to develop an exacerbation on reduction 
of their regular corticosteroid therapy. In their study, they found that the 
extent of control of eosinophilic airway inflammation and exacerbation was 
greater in the sputum management group, which targeted at lowering the 
airway inflammation, than in the BTS management group. They concluded 
that a treatment strategy targeted at normalization of sputum eosinophilia 
would reduce asthma exacerbations and hence a better asthma management. 
(Green RH et al., 2002) Similar study is lacking in the paediatric population 
but the same theoretical rationale should apply. 
In another study by Zacharasiewicz A et al., Forty children with stable 
asthma eligible for inhaled steroid reduction were recruited and reviewed 
every 8 weeks, and their inhaled steroid dose halved if clinically indicated. 
eNO, combined HSCSI, and exhaled breath condensate collection were 
performed at each visit to predict success or failure of reduction of inhaled 
steroids. Thirty of 40 (75%) children tolerated at least one dose reduction, 
•“ 12 of 40 (30%) were successfully weaned off, and in total, 15 of 40 (38%) 
children experienced loss of asthma control. Treatment reduction was 
successful in all children who had no eosinophils in induced sputum before 
. .the attempted reduction. By using multiple logistic regression, increased 
eNO (odds ratio, 6.3; confidence interval, 3.75-10.58) and percentage of 
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sputum eosinophils (odds ratio, 1.38; confidence interval, 1.06-1.81) were 
significant predictors of failed reduction. These findings suggest that 
monitoring airway inflammation may be useful in optimizing treatment in 
children with asthma. (Zacharasiewicz A et al., 2005) 
2.4.3 Role of sputum induction in differentiate types and causes of airway 
inflammation and treatment strategies 
Sputum induction can be used as an assessment tool in differentiating 
eosinophilic and non-eosinophilic inflammation. The differentiation is 
important with respect to treatment. An increase in sputum eosinophils is 
regarded as characteristic of asthma and can be induced by inhaled allergen 
(Gauvreau GM et al., 1996 & 1999) and by a reduction in steroid treatment 
in steroid dependent asthma. (Gibson PG et al., 1992; In't Veen JC et al., 
1999; Pizzichini MM et al., 1999) 
In healthy subjects, sputum differential cell counts show that 
macrophages and neutrophils predominate and eosinophils and lymphocytes 
are few. (Belda J et al., 2000) Abnormalities in differential cell counts 
re-emphasize the occurrence of different types of inflammation and their 
different causes. 
Persistent sputum eosinophilia in patients with "difficult asthma" 
should raise the possibility of under treatment or noncompliance with 
corticosteroid medication. Noncompliance can be confirmed by comparing 
, the level of sputum eosinophilia before and after direct supervision of 
administration of medication. (Parameswaran K et al., 1999) This issue is 
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particularly important in paediatric asthma as poor compliance has a direct 
link with frequent exacerbations. 
In addition, sputum induction can help to identify appropriate add on 
therapy in childhood asthma. Long acting beta-agonists significantly 
improve symptoms and pulmonary function but they could mask underlying 
airway inflammation as they do not possess anti-inflammatory action 
(Claman DM et al., 1994) Mclvor RA et al. has demonstrated that 
salmeterol controlled symptoms and lung function in asthmatic subjects 
undergoing corticosteroid withdrawal allowing greater sputum eosinophilia 
to develop before a clinically recognizable exacerbation. (Mclvor RA et al., 
1998) Gibson PG et al., has demonstrated that, on the other hand, long 
acting beta-agonists improve asthma control in symptomatic patients with 
normal cell counts on corticosteroid therapy (Gibson PG et al., 1999). 
For sputum neutrophilia, the known causes include chronic airflow 
limitation associated with cigarette smoking, (Pizzichini E et al., 1996; 
Stanescu D et al., 1996; Keatings VM et al., 1997) pollutants such as ozone 
(Fahy JV et al., 1995; Holz 0 et a l , 1999; Vagaggini B et al., 1999), 
endotoxin (Nightingale JA et al., 1998) and infection (Pizzichini MM et a l , 
1998). The intensity of the neutrophilia is indicated by the total cell count 
and is most pronounced in bronchial infection. The likely cause of 
non-eosinophilic but neutrophilic exacerbations of asthma is viral infection, 
(Fahy JV et al., 1995) although the cause and incidence has not been 
‘ -confirmed. (Pizzichini MM et al., 1998; In't Veen JC et a l , 1999) 
For normal sputum cell counts or neutrophilia with a normal total cell 
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count, other conditions such as gastroesophageal reflux (Parameswaran K et 
a l , 2000), habit cough need to be considered. 
2.4.4 Role of sputum induction in evaluating chronic cough in asthma 
Childhood chronic cough is a common and troublesome problem. It is 
a non-specific symptom that is associated with several unrelated 
mechanisms and has various causes including asthma. Sputum induction 
can be used to recognize eosinophilic bronchitis without asthma. (Gibson 
PG et al., 1989 & 1995) This condition was observed in patients with a 
chronic cough who had normal spirometry and normal airway 
responsiveness to methacholine and adenosine monophosphate. The sputum 
contained an increase in eosinophils, and this plus the chronic cough were 
reversed by corticosteroid treatment though eosinophilic bronchitis is rarely 
seen in children. 
Furthermore, it has been demonstrated that chronic cough usually is 
associated with predominant sputum neutrophilia, but up to 40% of subjects 
with cough have sputum eosinophil count of more than 3%. (Brightling CE 
et al., 1999; Gibson PG et a l , 2001) In chronic cough with sputum 
eosinophilia, inhaled steroids are usually effective but prednisone may be 
required transiently (Wong AG et al., 1996) or regularly (Hargreave FE et 
al., 1999). In contrast, chronic cough without sputum eosinophilia is not 
going to respond to corticosteroids (Pizzichini MM et al., 1999). Sputum 
induction in this scenario is a useful and cost effective tool for diagnosing 
‘ .the group of patients with chronic cough that is going to be responsive to 
anti-asthma therapy. 
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2.5 Problems of sputum induction in children 
The method of sputum induction has many advantages but it has a few 
major drawbacks that limit its use in daily clinical practice. The process of 
sputum induction needs dedicated, highly qualified laboratory technicians 
and the process is rather time consuming. From our experience, it can be 
estimated that even if a patient produces a suitable sputum sample within 10 
min of starting induction, the total time required for preparation of 
equipment, induction process, processing of the sample, staining and 
performing a differential cell count will amount to -180 min. The method 
has therefore been used mainly for research purposes and less often in 
clinical practice. 
In addition, the need to process sputum within 2 h after induction limits 
the number of patients that can be examined in parallel and restricts its use 
in most out-patient settings Storage of sputum could cause a lower quality 
of cytospins and a change in sputum compositions. (Bettschart RW et al., 
1998) Two methods were suggested in literature to overcome the problems. 
One method consists of simultaneous homogenization and fixation of 
freshly expectorated sputum with Saccomanno's fixative plus 0.2% 
dithiothreitol (DTT). (Nielsen L et al., 1998) Although it enables longer 
storage of sputum sample, cell counts are still difficult to perform due to 
" cellular shrinkage after fixation. The second method utilizes 
dimethylsulphoxide (DMSO) to freeze the sputum cells to avoid water 
crystallization. (Popov T et al., 1998) Although there is an impairment of 
‘ cellular morphology, the extent does not affect the differential cell count. 
Preliminary data show a good correlation between frozen samples and 
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corresponding freshly processed aliquots. (Holz O et a l , 1999) 
Gibson PG et a l , has demonstrated a different approach to simplify 
sputum analysis. He and his colleagues lysed the cell pellet after 
homogenization and measured the amount of eosinophilic cationic protein 
(ECP) released as a marker, instead of preparing cytospins to quantify 
eosinophils. (Gibson PG et al., 1998) This automatic method requires � 3 
hours for analysis of ECP and a good correlation between the number of 
eosinophils and the concentration of ECP in the cell lysate suggests that this 
could be an easier way to perform large scale studies. However, further 
evidence and validation are needed 
In order to incorporate sputum induction as a cost effective tool in our 
routine clinical practice, the time and manpower needed for processing have 
to be shortened. Sputum induction in its current state is generally considered 
as a research tool only, but it is rapidly being recognized as a useful adjunct 
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2.6 Conclusion 
Diagnosis and assessment of asthma has traditionally been relied on 
clinical history，which depends on the integrity of patients and the accuracy 
of the reporting, which is subjective in nature. Lung function tests such as 
spirometry and peak flow measurement indirectly reflect the degree airway 
inflammation. Examination of cellularity by means of BAL or 
bronchoscopy is the gold standard in assessing airway inflammation; 
however, they are invasive, expensive and potentially hazardous in children. 
Since controlling airway inflammation is the core of asthma management, 
non-invasive markers of airway inflammation are needed to guide clinical 
practice and for research purposes. Therefore, HSCSI has become an 
attractive assessment tool in assessing asthma severity as it can assess 
airway inflammation as well as airway hyper-responsiveness at the same 
time in a non-invasive manner. 
Sputum induction in children is currently regarded as a useful 
technique in assessing airway inflammation because of its non-invasive 
nature. It has its place and value in clinical practice such as assessing the 
airway inflammation in persistence asthma, evaluating the efficacy of 
inhaled corticosteroid in reducing sputum eosinophilia, distinguishing the 
eosinophilic asthma from the non-eosinophilic asthma, and predicting 
“ asthma exacerbation. However, the long induction and processing time 
limits its regular use in the outpatient clinic. 
I » 
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Chapter 3 HSCSI — Methodology and Materials 
3.1 Introduction 
Hypertonic saline aerosols are potent stimuli for airflow limitation in 
asthmatics, whereas normal subjects only rarely react (Schoeffel RE et al., 
1981; Anderson SD et al., 1983; Smith CM & Anderson SD, 1986; Araki H 
& Sly PD, 1989; Riedler J et a l , 1994). The potential for aerosols of 
hypertonic solutions to be used for airway provocation testing was first 
recognized in 1981. (Schoeffel RE et al., 1981) From the studies of 
Schoeffel and Smith (Smith CM & Anderson SD, 1986), it was apparent 
that the rate of change of the airway osmolarity was an important 
determinant for a positive response in an asthmatic. Therefore, a more 
concentrated hypertonic saline (4.5%) is now used rather than the original 
concentration (3.6%) reported in 1983. (Anderson SD et al., 1983) The 
original protocol, which is used for adults, has been slightly modified for 
use in children by Riedler et al. (Riedler J et al., 1994 & 1998; Riedler J & 
Robertson CF，1994). 
The protocol for combined HSCSI described here has been 
successfully implemented in our paediatric pulmonary function laboratory 
at Prince of Wales Hospital. The protocol was chosen over others because it 
was the best described, and has been shown to be practical and safe for use 
• both in adults and children. 
I » 
35 
Chapter 3 Material and Methodology 
Baseline FEVl 
Measurement : 
Inhalation of 4.5% ^  
hypertonic saline 
/ R e p e a t 6 c y c l e ^ 
with different collect sputum 
V duration J 
^ FEVl  
Measurement 
Complete 6 cycles / FEV1 drop >20% from Baseline 
_ � 
f l^uffs 一wait1�min— Post FEVl 
ventolin given measurement 
Duration : 30s, Imin, 2min, 4min, 4min, 4min 
Fig. 3.1 Procedures for combined HSCSI 
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3.2 HSCSI - Methodology 
3.2.1 Patient preparation 
Medications used in treatment of asthma have been found to inhibit or 
even completely prevent responses to the hypertonic saline challenge. 
Therefore, patients should withhold their pulmonary medications for the 
appropriate times before hypertonic saline challenge - no short acting 
bronchodilators, sodium cromoglycate, nedocromil sodium, or ipratropium 
bromide for 8 hours; no long acting or sustained-release bronchodilators or 
antihistamines for 48 hours; or leukotriene antagonist for 4 days. (Kemp JP 
et a l , 1998) 
No caffeine should be taken on the morning of the study, although 
some laboratories request 24 hours withholding of beverages or food 
containing caffeine. No vigorous exercise should be undertaken for at least 
4 hours before attendance at the laboratory, and it would be preferable to 
have no vigorous exercise on the day of study (Dessanges JF et al., 1999) 
because of the possibility of cross-refractoriness. Steroids can be withheld 
on the day of the study, but this is flexible depending on the question being 
investigated. In addition, recent exposure to allergens, respiratory infection, 
and cigarette smoke may affect responses to the hypertonic saline challenge 
test. 
HSCSI is performed in a dedicated area with negative pressure 
facilities. Before the start of the procedure, the patient is examined by a 
, physician and his temperature is checked. The procedure will be thoroughly 
explained to the patient and the technique of proper coughing and 
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expectoration are demonstrated. Relatives and parents are asked to wait 
outside the laboratory to minimize interference. During the procedure, a 
medical personnel is usually present during the process and in addition 
bronchodilators together with other essential resuscitation equipments are 
readily available. 
Fig. 3.2 Laboratory for combined HSCSI (7/F Ward AB Treatment Room) 
3.2.2 Hypertonic saline preparation 
Preservative-free sterile solutions of 4.5% saline are prepared; about 
200 - 250ml of the solution is required for each challenge. The solution is 
disregarded after a single use. The solution should be refrigerated at 4 � C and 
warmed to room temperature (21 - 23°C) for 30 min before use, as low 
temperatures may reduce the output of aerosol from the ultrasonic nebulizer. 
I » 
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Fig. 3.3 4.5% Hypertonic saline and nebulizer cup 
3.2.3 Equipments and materials 
• Refrigerator for the storage of 4.5% hypertonic saline and specimen 
• ULTRA-NEBTM ultrasonic nebuliser, model 2000, on the maximum 
output setting (DeVilbus) 
• Salbutamol with a spacer device 
• Stop watch 
I I I III 
；‘ 
• Hans Rudolph valve box, large 2 way no. 2700 (Fig 3.4) 
i » 
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• VacuMed 1001 mouthpiece (Fig. 3.5) 
_ 
• Spirometer (Spirolab II, MIR, Italy) and mouthpiece (Fig. 3.6) 
• Sputum collection jar 
• Calculator and record sheet (Appendix I) 
• Nose clip 
• Absorbent sheet on which to place valve box 
• Benchtop Digital Scales 
3.2.4 Aerosol generation and delivery 
Ultrasonic nebulizers are used to generate high density hypertonic 
saline aerosols. It is important to ensure that the particle size generated is 
suitable and that the actual volume of output of the nebulizer is sufficient 
for airway provocation testing. Nebulizer with large volume canisters 
(400ml capacity) which can be easily detached for weighing will be suitable 
‘for the use in the procedure. 
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Fig. 3.6 Assembled DeVilbis 2000 Nebulizer filled with 4.5% hypertonic saline, 
Hans Rudolph valve box and mouthpieces in Nuaire Biological Safety 
Cabinets Class II Type B2. 
DeVilbis 2000 produces aerosol particles of 2 - 6 |j.g when water is 
used. After passing through the tubing and valve that filter and trap large 
particles, the dispersion profile of the aerosol particles inhaled by the 
, subject may be very different from the profile of those leaving the canister. 
When the tubing and valve is attached, a minimum output of 1.5mL/min is 
recommended, although a minimum output of 1.2mL/min is sufficient for 




Chapter 3 Material and Methodology 
M 
Fig. 3.7 4.5% hypertonic saline aerosol 
The following factors will affect the output of aerosol from the 
nebulizer and the dose delivered to the child. 
• The room temperature for the nebulizer to operate should be 21°C 
or above an initial exposure to lower temperatures results in lower 
output by the nebulizer, especially DeVilbis. 
. 眷 The output can vary with the volume of fluid in the nebulizer 
(Anderson SD & Schoeffel RE, 1985), so a constant starting 
volume between 200 - 250mL is recommended. (Anderson SD et 
„ al., 1995) 
參 The nebulizer output is decreased with use of two-way valves, as 
aerosol particles impact on neoprene diaphragms. Multiple small 
valves such as Hans Rudolph Series 7200 should not be used. 
I 
» 
‘ Hans Rudolph Series 2700 is recommended for both adults and 
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children. The advantage in using valve system is that the aerosol 
is not dissipated when the subject exhales; instead, it accumulates 
in the tubing and canister and is inhaled with the next breath. 
參 Face masks are not recommended as excessive amounts of aerosol 
can be accidentally delivered by this techniques. The nebulizer 
output may be reduced to an unacceptable value (<1.2mL/min) by 
the use of a disposable medication cup, thus leading to 
false-negative tests. 
參 The main canister is used to hold the solution rather than a cup 
unless there is a question of hygiene, in which case the cup device 
should be used. 
• The condensate on the tubing that falls back into the canister 
should not be in contact with the patient because there is a valve 
on the inspiratory port. 
參 Tubing with a smooth interior surface, 60 - 70cm long with an 
internal diameter of 22mm is recommended. The longer the 
tubing between the canister and valve, the fewer aerosols will be 
delivered to the inspiratory port of the two way valve. 
參 The dose delivered can vary according to the tidal volume of the 
subject. Riedler et al observed very large variations in children 
(Riedler et al., 1994) 
•“ 參 The nebulizer output can diminish over many months of regular 
use, and the piezo electric crystal may need to be changed. Loss 
of output should be detected readily, as the volume delivered to 
, , each patient is recorded by weighting. 
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• The canister and tubing, but not the valve are weighted before and 
after the challenge and can be weighted during the challenge. 
• Care must be taken to allow the solution that has collected in the 
tubing to run back into the nebulizer canister. The valve is not 
weighted because it frequently contains saliva. 
• It is recommended that once the nebulizer is characterized, the 
tubing and valve remain the same and the same nebulizer is used 
for the same person if multiple tests are performed. 
I » 
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3.3 Protocol for combined HSCSI 
1 Place 250ml of 4.5% hypertonic saline into the nebuliser cup and 
weight along the cover and the delivery tube but does not including the 
two way valve 
2 Ascertain that medication has been withheld for the specified time and 
document the type, amount and time of last medication. 
3 Explain the purpose of the test to the subject - how it is conducted and 
possible side effects e.g. cough, dry mouth, gagging, chest tightness, 
wheezing, dyspnoea, nausea and excess salivation. 
4 Instruct and demonstrate how to obtain sputum from the lungs by 
coughing and clearing throat. 
5 Perform baseline spirometry (FEVi and FVC) 
6 Calculate a 20% fall of the highest FEVi and record (FEV, x 0.8 
=20%). 
7 Ask the subject to rinse his/her mouth in order to eliminate squamous 
cell contamination of the specimen. 
8 Ask the subject to apply the nose clip and insert the mouthpiece into 
their mouth, in a similar manner to a snorkel. 
9 When the subject is comfortable, turn on the nebulizer and start the 
stopwatch. Instruct the subject to breath "normally" (tidal breathing) 
through the mouthpiece. Turn the machine off after thirty seconds have 
elapsed. 
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11 Place the mouthpiece, opening down, on the absorbent sheet so any 
excess residue can be drained. This prevents a potential backwash of 
pooled secretions through the one way valve. 
12 Wait for 60 seconds after each nebulisation episode in order to record 
maximal bronchoconstriction. 
13 FEVi is recorded at the end of one minute. The nebulisation resumes 
immediately after the percentage of FEVi fall has been calculated. 
14 The dose is cumulative over the time of challenge. Keep time for 
spirometry at each dose level to a minimum to ensure cumulative 
effects. 
15 Percentage fall of F E V . = (Baseline FEVI - FEVI) x 100 
Baseline FEVI 
16 Repeat steps 11-14，increasing the nebulisation time by doubling the 
time period: one minute, two minutes, and three periods of 4 minutes. 
17 Between each period, there is a one minute break before the FEVi is 
recorded. Use this time to encourage the subject to produce sputum. 
Ask them to cough, clear their throat and deposit all or any oral 
contents into the specimen container. 
18 It usually takes a cumulative time of about 11 minutes to produce an 
adequate specimen. Listen for a moist cough as a sign the subject is 
ready to produce sputum. 
19 If the FEVi falls below 20% and there is not enough sputum produced, 
instruct the subject to inhale a beta-agonist and wait for 10 minutes, or 
until the FEVi has returned to within 10% of the baseline measurement. 
20 Restart the nebulisation of 4.5% hypertonic saline, delivered in 4 
I 
‘ minute doses, until sputum is obtained or a cumulative nebulisation 
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time of 20 minutes is reached. The nebulisation time is continued at 2 
minute intervals if the subject demonstrates severe airway 
hyper-responsiveness to 4.5% saline (PD20 is < 2ml). 
21 Once an adequate specimen has been obtained, refrigerate. Processing 
must take place within a maximum of 4 hours. 
22 Stop the nebulisation if: 
a) An adequate specimen has been produced and the FEVi has 
dropped 20% 
b) An adequate specimen has been produced and the cumulative 
nebulisation time is 20 minutes 
c) The subject requests the nebulisation to stop. 
23 Ensure the subject's FEVi has returned to within 10% of the baseline 
measurement and that they are experiencing minimal discomfort before 
allowing them to leave a supervised area. 
24 Following the end of the procedure once again weigh to 1 decimal 
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Fig. 3.8 Lung function measurement during combined HSCSI 
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Fig. 3.9 Inhalation of 4.5% hypertonic saline by in combined HSCSI 
t 
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3.4 Practical considerations in HSCSI 
參 If the subject is clinically unstable, or becomes symptomatic during the 
procedure, caution should be exercised when determining the length of 
each nebulisation. 
• Monitor the FEVi at 1 to 2 minute intervals during each nebulisation if 
there is reason for concern. 
• If the subject wishes to cough during the procedure, they should be 
encouraged to cough into the nebuliser and not remove the mouthpiece 
• Between nebulisations encourage coughing in order to obtain a 
specimen. Many subjects will cough immediately the nebulisation 
finishes. This opportunity can be used to obtain sputum but exercise 
moderation so as to not tire the subject or cause a sore throat. 
• Listen to the subject to ensure the sample is from the lungs and not post 
nasal secretions. 
• All sputum induction procedures should be conducted in areas where in 
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3.5 Expression of airway response 
The airway responsiveness to hypertonic aerosols is expressed as the 
dose of 4.5% saline required to provoke 20% fall in FEVi. To calculate this, 
the response-dose curve can be constructed - expresses as a percentage of 
the baseline value for FEVi (fall in FEVi) against the cumulative dose of 
aerosol. 
The cumulative dose of aerosol is determined for each time interval by 
dividing the total dose delivered to the inspiratory port of the two-way valve 
divided by the total time for delivery. 
The percentage fall in FEVi is plotted against the cumulative dose. A 
PD20 value can be obtained by linear interpolation, and is expressed in ml. 
One ml of 4.5% saline is assumed to be 1 g, but the factor for relative 
density (1.003) can be used to correct the volume. 
PD20 < 2mls Severe hyperresponsiveness 
2.1 - 3.0 Moderate - severe hyperresponsiveness 
3.1 -6 .0 Moderate hyperresponsiveness 
> 6mls Mild hyperresponsiveness 
Table 3.1 Interpretation of PDzoin HSCSI 
It is acknowledged that the dose that enters and deposits in the airways, 
but using the technique and equipment described, it is estimated that 20% of 
. the hypertonic saline will reach the lower airways. (Anderson SD et al., 1995; 
“ Gonda I, 1986) 
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Dose-Response Cur\e 
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3.6 Safety issue in HSCSI 
The hypertonic saline solution is best prepared by a trained person such 
as pharmacist. It is recommended that two people familiar with the 
standardized protocol, symptoms, signs of respiratory distress, and safety 
procedures, be in attendance or nearby. 
If a subject appears to be distressed during the challenge, the 
ventilation is reduced, or the oxygen saturation is falling, the challenge 
should cease. Under these circumstances, an FEVi measurement is made 
immediately and a bronchodilator administered if required. 
It is usual to administer a bronchodilator at the completion of study to 
anyone who has 10% or greater fall in FEVi. A person should always stay 
with a subject after challenge in order to make FEVi measurements and to 
ensure recovery to baseline of lung function. 
The protocol described here was suitable for mild or well-controlled 
asthmatics; those with severe disease often have reductions in FEVi of 40% 
or more, even when the pre-challenge lung function is normal. The situation 
can rapidly reverse after inhaling a bronchodilator. 
If the subject is taking beta agonists either short acting or long acting 
on a daily basis; the dose required to reverse the induced changes in FEVi 
may be 2 to 3 times greater than the clinically recommended dose. (Hancox 
. ,RJ et al., 2002) 
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The bronchodilator can be delivered using a large or small volume 
spacer device. In the cases of severe bronchoconstriction, oxygen should be 
administered together with bronchodilator. The equipment to make 
measurements and to administer a bronchodilator must be portable. Some 
form transportation should be available to allow rapid access to the nearest 
emergency department. 
_ 
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3.7 Approach in our studies 
HSCSI is an important tool in assessing airway hyperresponsiveness, 
especially in distinguishing mild, moderate and severe asthma. In our 
following studies, all of our subjects were clinically classified as stable and 
mild asthma and no severe asthma subjects recruited. Therefore, we 
concentrated on the interpretation of sputum differential cell counts instead 
of airway response as a technique in the management of childhood asthma 
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3.8 Sputum processing 
Sputum obtained in hypertonic saline challenges and sputum induction 
is a variable mixture of tracheobronchial secretions, saliva and hypertonic 
saline. The contamination of saliva is considered as a problem as it can 
confound the interpretation of the results. In order to cope with this problem, 
the sputum plugs are generally selected to reduce contamination with upper 
respiratory tract material (although not all groups do this), and the cells 
dissociated from mucus using a reducing agent such as dithiothreitol (DTT). 
Good quality cytoslides can be routinely obtained and a reliable cell 
differential generated. (Fahy JV et al., 1993; Gibson PG et al., 1989; Pavord 
ID et al., 1997) 
3.8.1 Sputum sample for processing 
Some asthmatics, in particular those with acute exacerbations or severe 
current symptoms produce sputum spontaneously. (Schoonbrood DF et al., 
1994; Hill AT et al., 1999) Spontaneously sputum contains similar 
percentages of inflammatory cells and mediators to induced sputum. 
However, cell viability in spontaneous sputum is considerably lower than 
that in induced sputum (Pizzichini MM et al., 1996; Bhowmik A et al., 1998) 
and the quality of samples is poorer, particularly in patients with more 
severe asthma (Bartoli ML et al., 2002). The reason is possible that a longer 
residence time of mucus secreted into the airways leads to reduced cell 
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Induced sputum obtained from hypertonic saline challenge is actually a 
variable mixture of tracheobronchial secretions, saliva and hypertonic saline. 
Saliva is a contaminant that can confound the interpretation of sputum 
results. There are two methods in dealing with the salivary contamination. 
They are the selected sputum method and the whole sputum method. 
Selected sputum method minimized salivary contamination by microscopic 
selection of viscid mucocellular portions of sputum for analysis. (Gibson 
PG et al., 1989; Pin I et al.，1992) In whole sputum method, the sample 
collected is analysed as a whole, ie sputum and saliva together; the salivary 
results are subtracted from the sputum results to give a "corrected 
cell-count". (Fahy JV et a l , 1993) At present, there are no recommendations 
or guidelines to indicate which method should be used under what 
circumstances because insufficient comparative studies have been 
conducted. Both methods have been shown to be useful in assessing airway 
inflammation in adults; however, studies have shown that the selected 
sputum method may provide more viable cells, more eosinophils and a 
higher concentration of eosinophil cationic protein (ECP) (Spanevello A et 
al., 1998). Although there are no formal comparisons between two methods, 
the majority of studies in children have used the selected sputum method 
and only two studies have used the whole sputum method. (Grootendorst 
DC et al., 1999; JW et a l , 1999) Therefore, we manually select viscid 
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Fig. 3.13 Selected sputum method 
3.8.2 Method for sputum processing 
The sputum sample must be placed in ice after collected and dispersed 
within 2 hours at 4°C prior to cytocentrifugation to avoid cell and mediator 
degradation. (Pizzichini MM et al., 1996) 
The examination of unprocessed smears has the disadvantage of 
sampling only a circumscribed part of the sputum. In addition, leucocytes 
may be entrapped in mucus and aggregated, making them difficult to 
identify. Dithiothreitol (DTT) is used to disperse sputum sample by 
breaking up disulfide bonds in the large mucin molecules which enable the 
release of cells and mediators from the mucus. Thus a monolayer of sputum 
cells is generated (Fleury-Feith J et a l , 1987) and allowing the qualification 
and characterization of cells to be more reliable. (Pizzichini E et al., 1996) 
( 
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DTT has been shown to be far superior for making high-quality 
cytospins, but it can interfere with the detection of soluble mediators by way 
of their effects on disulfide bonds, as is the case with chemokines. This 
makes soluble mediators susceptible to denaturation by DTT thus 
potentially altering epitopes and the immunological detection of these 
proteins. DTT appears not to affect detection of interleukin-5 and fibrinogen, 
but clearly increases the detectable levels of ECP and IgA, (Louis R et al., 
1999) not because of cell activation but because of increased release from 
mucins. After the dispersion of sputum sample and cytocentrifugation, the 
cytoslides is stained and 400 non-squamous cells are counted. 
Combining hypertonic saline challenge with sputum induction allows 
the assessment of bronchial hyper-responsiveness and degree of airway 
inflammation during the same procedure. In adult patients, hypertonic saline 
challenge has been shown to be sensitive, reliable and it correlates better 
with serum markers of inflammation than methacholine challenge. (Sont JK 
et al., 1993) Whether the same holds true for childhood asthma remains to 
be seen. Although combined hypertonic saline challenge with sputum 
induction provides a useful means to compare airway hyper-responsiveness 
and airway inflammation at the same time, it was reported that its success 
rate in obtaining adequate sputum allowing for the preparation of good 
' quality cytoslides for differential cell count was lower than sputum 
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Sputum induction is performed using an inhalation of 4.5% hypertonic 
saline (HS) through a mouthpiece and large two-way non-rebreathing valve 
(Hans Rudolph 2700, Hans Rudolph Inc, Kansas City USA) connected to a 
DeVilbiss ultrasonic nebulizer set at the maximum output (6 litres/minute). 
The child is asked to rinse his mouth with water to clear debris and 
squamous epithelial cells. A nose-clip is worn and baseline forced 
expiratory volume in 1 second (FEVi) is measured. Sputum induction is 
only carried out if the subject's FEVi is at least 65% predicted using local 
reference values. The child then inhales HS for a period of 30 seconds. 
Lung function is repeated 1 minute after the inhalation. If no sputum is 
obtained and lung function remains greater than 80% of the baseline value, 
the test continues. The child then continues inhalation of HS for periods of 
1 min, 2 min, and then three periods of 4 min each. He is encouraged to 
cough up any sputum after each dose of HS and the sputum sample is 
collected in a specimen bottle, kept at 4�C，and processed within 2 hours. A 
record of any side effects experienced by the child undertaking the test and 
repeat measurements of FEVi are made at the end of each elapsed inhalation 
time period. The study concludes either when the child develops 
troublesome symptoms, when lung function drops below 80% of the 
baseline value, or if the child cannot be persuaded to complete the whole 
inhalation procedure. If the child has a greater than 20% drop in FEVi, 500 
meg of salbutamol is administered using a metered-dose inhaler with a 
spacer, and recovery monitored. The subject is allowed to leave only when 
the FEVi returns to its baseline value. We will also stop the procedure if no 
. ,sputum is obtained after 20 minutes of inhalation despite stable FEVi. For 
sputum processing, our laboratory uses the selected sputum plug method as 
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described above. The volume of the selected sputum is measured and 0.1% 
dithiothreitol (DTT) (Sigma Chemicals, Poole, UK) is added to the sputum 
in a 4:1 ratio in order to break up the disulfide bonds and disperse the cells. 
The cell suspension is aspirated until homogenized and filtered to remove 
any remaining debris. Phosphate buffered saline is then added to the cell 
suspension. The non-squamous cell count and cell viability (with trypan 
blue) are determined in a haemocytometer. The cell suspension is 
centrifuged at 400G for 10min and cytospins are made and stained by 
May-Griunwald Giemsa stain. 400 non-squamous cells are counted and 
adequate sample is defined as having less than 50% squamous cell. The 
eosinophil count is then expressed as a percentage of total cell count. 
3.8.3 Equipment and material for sputum processing 
Equipment: 
• Observation base plate (black) 
• Inverted microscope 
• 100|al Positive displacement Pipettes with tips 
• Thermoline Shaking water bath 22°C 
• Centrifuge 
• Millipore nylon filter 60^il and filter holders 
• Haemocytometer and cover slip 
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Material: 
• Sputolysin (0.01 g DTT + 10ml PBS) 
• Trypan Blue 
• Distilled water 
• PBS 
• Petri dish 
• Glass slides 
• Disposable Pipettes 
• 15ml falcon tubes 
• 2.5ml and 10ml syringes 
• 1.5ml eppendorf tubes 
3.8.4 Protocol for sputum processing using selected sputum method 
1. Fill out the sputum worksheet details for visit number and collection 
details (include worksheet - Appendix I) 
2. Invert sputum sample jar into a clean open petri dish in the hood 
3. Use clean forceps to separate mucus clumps from saliva bubbles 
4. Evaluate quality of sputum (volume, color and number of mucus 
clumps) 
Remarks: 
參 Small white space 1,5mm x 3mm on observation base plate is the 
size of 1 mucus clumps 
• If it is uncertain whether the sample contains lower respiratory 
clumps, inspect sample in petri dish using inverted microscope 
, , and find the non-squamous cell areas 
5. Use forceps to pull up all mucus clumps 
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6. Make Sputolysin 1:10 (1ml stock solution to 9ml distilled water in 
15ml falcon tube) Label tube with date made and initials. 
Remark: The stock solution is stable for 48hours at 4 
7. Label 15ml falcon tube with patient Lab number 
8. Pipette all suitable mucus clumps (minimum lOO i^l but <1 ml) into 
‘ labeled 15ml tube by a positive displacement pipette. Record the actual 
volume of the mucus used on the worksheets 
9. Add 4 times the volume of diluted Sputolysin to sample in tube, mix 
up and down with disposable pipette (e.g. 300^1 sputum + 1.2ml 
diluted sputolysin) 
10. Cap tube and place in shaking water bath at 22°C for 30 minutes to 
dissolve mucus 
11. Add the same volume of PBS as Sputolysin (e.g. 300^1 sputum + 
1.2ml PBS) and mix with a disposable pipette and shake for further 5 
minutes in water bath 
12. Filter sputum and sputolysin mixture through nylon filter apparatus 
Procedure: 
• Wet filter with PBS prior to filtering sample to ensure no loss of 
sample during filtering. 
• Insert 2.5 / 5 / 10ml syringe (depending on volume to be filtered) 
into mixing cannula. 
• Use syringe to draw up sample then slowly filter sputum and 
sputolysin mixture through nylon mesh filter and down the side of 
the tube (1 drop per Is) 
, , 1 3 . Record the post-filtered volume on data sheet (used for total cell count, 
‘ TCC) 
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14. Mix 20|il sample with 20[i\ Trypan Blue into a eppendorf tube 
15. Pipette 20|al mixture onto the Haemocytometer 
16. Use a light microscope to perform a Total Cell Count 
17. Centrifuge the remaining cell suspension at 400G / 1600rpm for 10 
minutes 
‘ 18. Evenly aspirate the supernatant into eppendorf tubes labeled with a lab 
number and freeze immediately at -20 / - 70 
19. Resuspend the pellet in a volume of PBS determined by the following 
equation: 
V2 = Total cell count/ml x Post Filtered Volume (VI) 
20. Assemble Cytospin apparatus (slide, filter paper, sample bucket, and 
metal clip), making sure that the filter card circle lines up with the 
filter cup circle by observing the reverse side of the metal clip when 
assembled. 
21. Using disposable pipette add required volume (V2) of PBS to dry cell 
pellet, mix up and down a few times to ensure sample is completely 
dispersed (sample now at 1 x 10^ cells per ml) 
22. Add 70|aL of the sample to each cytospin sample bucket, and 
centrifuge sample (500 rpm for 5 minutes) 
23. Carefully and quickly remove cytospins from apparatus, making sure 
to flip off the filter paper, air dry slides. Label with a lab number and 
the appropriate fixative, leaving spare slides labelled but unfixed. 
24. If DTT is still in date, put in the fridge. (DTT lasts for two days after it 
has been made) 
I 
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Remarks: Calculation: 
Formula to calculate TCC and viability: 
—inflammatory cell count 乂 q q ) 
TCC — number of quadrants ^ • 
= x.xxx l O V l 
number of live cells , „„ 
% Viability = total number of cells 乂 贈 
3.8.5 Equipment and Material for May Gruneald - Giemsa (MGG) staining 
Equipment: ‘ 
• Coplin Jars 
• 100mm Glass Funnel 
• Tripod 
• 5 0 - 1 OOmL Glass Measuring Cylinder 
• 200mL Glass Beaker 
• Filter Paper - Whatmans Grade 1 (DMB Cat no: F110) 
• Tweezers 
• Microscope 
• Glass pipette 
• • Macropipette controller 
• Aluminium or stainless steel tray 
• Glass coverslips - 22 x 22mm (DMB Cat no: MHO) 
‘ • Glass screw top jar 
Materials: 
• May and Grunwald stain (Australian Scientific Cat no: 35025 4R) 
• Giemsa (Australian Scientific Cat no: 35014 4M) 
< 
'' • Ethanol 
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• pH 6.8 Buffer Tablets (Australian Scientific Cat no: 33199) 
‘ • Distilled water 
• Incohelp Pads (Oracle Cat no: M 12796) 
• DPX (Australian Scientific Cat no: 36029 4H) 
• Tissues 
‘ • Pasteur pipette (Uni store: Cat no: P250) 
• 50mL Falcon Tubes (Uni store Cat no: T280) 
3.8.6 Protocol for May Gruneald - Giemsa (MGG) staining 
Before experiment: 
1. Prepare the pH 6.8 buffer by dissolving 1 buffer tablet in lOOOmL of 
distilled water 
2. The Giemsa solution is made up by adding 5mL of Giemsa to 45mL of 
pH 6.8 buffer solution 
3. The filter paper is folded in half four times 
4. Place the funnel in the tripod, and the filter paper in the funnel, place 
this over a coplin jar 
5. Pour the Giemsa solution into the funnel, which is positioned, over the 
glass coplin jar 
6. Pour approximately 50mL of May and Grunwald into a glass coplin jar. 
This is stable for 3 months (Label with Expiry date) 
‘ 7. Place tap water into water jars 
8. Place 100% ethanol into fixative jars 
I » 
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Staining Procedure: 
1. Place slides in 100% ethanol for 10 minutes 
2. Move the slides from the ethanol to the coplin jar containing the May 
and Grunwald 
3. Stain in May and Grunwald for 10 minutes 
4. Move the slides to a coplin jar containing water and give slides a rinse 
to remove excess stain 
5. Remove from the water and place in the Giemsa solution for 5 minutes 
6. Wash in water twice, by placing the coplin jar under running tap water, 
then emptying the jar and repeating this step. 
7. Wipe back of slides with Kimwipes (be careful not to wipe the wrong 
side, as this will remove the cells) 
8. Allow slides to airdry 
9. Add Coverslip to slides 
參 Lay slides on bench, cell side up 
• Get out coverslips as required, and line them up with the slides 
參 Put a drop of DPX on the coverslip using a pasteur pipette that 
has had about a centimeter cut off the end 
眷 Slowly lower the slide onto the coverslip ensuring that the 
mountant covers the cells with no air bubbles 
10. Place back up the other way and let the mountant dry 
“ 11. The next day a differential count will be done 
I 
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Treat and 
Selection of sputum 
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Fig. 3.14 Illustrated diagram for sputum processing. (Gibson PG et al, 
2000) 
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3.9 Interpretation of sputum differential cell counts 
Differential cell counts on sputum cytopsins have good inter-observer 
consistency. (Boulet LP et al., 1987; Pin I，1992; Popov T et al., 1994; 
Gelder CM et al., 1995; Pizzichini E et al., 1996) The repeatability of 
differential cell counts obtained on different days from clinically stable 
patients has been reported to be good. (Boulet LP et al., 1987; in 't Veen JC 
et a l , 1996; Pizzichini E et al., 1996) 
The normal ranges for sputum cell counts have been established by Cai 
Y et al. (Cai Y et al., 1998). The dominant cell in sputum from normal 
children is the macrophage, and the upper normal limit for sputum 
eosinophils in children is 2.5%. 
Table 3.1 Sputum cell count for normal, atopic normal and nonatopic 
normal children (Cai Y et al., 1998) 
Normal Atopic normal Nonatopic normal 
TCC 106 cells / ml 5.14 (1.2 - 9.08); 1.75 (0.89 - 2.6); 8.04 (0.63 一 15.5); 
1.5 (0 .8 -3 .9 ) 1.0 (0.55 - 2 . 1 5 ) 1.8 (1.05 - 6 ) 
Eosinophils % 1.57 (0.62 — 2.52); 2.16 (0.83 - 3.48); 1.13 (0 — 2.54); 
0 .3(0-1 .05) 0 . 5 ( 0 - 2 . 8 ) 0 ( 0 - 0 . 6 ) 
Mast Cells % 0.024 (0 - 0.05); 0.03 (0 — 0.07); 0.02 (0 - 0.06); 
0 ( 0 - 0 ) 0 ( 0 - 0 ) 0 ( 0 - 0 ) 
Data are presented as mean (95% confidence interval); median (interquartile 
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Table 3.2 Sputum cell counts in normal subjects (NC), controlled asthma (CA) on 
inhaled corticosteroid, symptomatic asthma (SA) and those with exacerbation of 
asthma (EA) (Cai Y et al., 1998) 
NC CA SA EA 
N = 72 N = 15 N = 16 N = 11 
TCC 106 cel ls /ml 1.5(0.8,3.9) 1.9(1.0, 7.5) 1.7(0.9,4.1) 2.5(1.6,5.4) 
Eosinophils % 0.3 (0，1.05)+ 2.5 (1.5, 0.75) 3.8 (2.4, 15.1) 8.5 (1.5, 20.0) 
Neutrophils % 35 (12.0，88.0) 46.5 (29.5, 58.5) 47.0 (24.8, 57.8) 27.0 (22.5, 42.0) 
Epithelial cell % 1.5 (0.8，3.0) 10.5 (5.0，17.5) 11.5 (5.5，21.3) 18.0 (6.0, 28.0) 
Values are presented as median and interquartile range, or as absolute number or 
percentage.+:p二0.0005，using Kruskal Wallis test. N = 47 for total cell count (TCC) 
from normal subjects. 
Mast cells are seldom seen in the sputum of healthy children (Pin I et 
al., 1992; Cai Y et a l , 1998; Gibson PG et al., 1998). They may be 
infrequently seen in sputum from children with asthma, where their levels 
are correlated with airway responsiveness to 4.5% saline. (Gibson PG et al., 
1998) 
Shed epithelial cells can be detected in sputum in increased numbers in 
unstable asthma. (Cai Y et al., 1998) When asthma control improves with 
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Sputum eosinophil counts may reflect different severity of childhood 
asthma. Elevated level of sputum eosinophil counts are seen in 
exacerbations and acute asthma (Twaddell SH et al., 1996; Cai Y et al., 
1998; Oh JW et al., 1999; Gibson PG et a l , 1999; Norzila M et a l , 2000) 
Sputum eosinophil cell counts decreases after corticosteroid therapy. (Oh 
JW et a l , 1999) Sputum eosinophils correlate well with other objective 
markers of airway inflammation. Studies comparing bronchial wash and 
bronchoalveolar lavage (BAL) to induced sputum in adults show that there 
is good agreement between the type of cells recovered by sputum and 
bronchoscopic samples. (Grootendorst DC et al., 1997; Pizzichini E et al., 
1998) Selected sputum is more concentrated than BAL fluid, having a 
higher density of recovered cells and higher levels of fluid-phase markers 
(Pizzichini E et a l , 1998). 
Sputum eosinophilia has a sensitivity of 70% and specificity of 90% in 
differentiation of asthma subjects from normal control when compared to 
serum ECP level, which has a sensitivity of 50% and specificity of 50% 
(Pizzichini E et al., 1997). In children, sputum ECP level was not correlated 
with serum ECP level (Piacentini GL et al., 1999) and the improvement in 
clinical asthma with inhaled corticosteroids was associated with a fall in 
sputum ECP level but no change in serum ECP level. (Sorva R et a l , 1997) 
.. Higher levels of induced sputum eosinophils are associated with greater 
airflow obstruction as reflected by a reduced forced expiratory volume in 
one second (FEVi) (Twaddell SH et al., 1996; Sorva R et a l , 1997； 
- ,Grootendorst DC, et al.，1999; Timmins N et al., 2000). The same 
association is reported in severe asthma, in which sputum eosinophil counts 
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correlated with the degree of airflow obstruction in children attending the 
emergency department with severe asthma (Piacentini GL et al., 1998). 
Degree of sputum eosinophilia is also associated with the degree of 
airway responsiveness, (Gibson PG et al., 1998; Piacentini GL et a l , 1998; 
Pin I et al., 1993) and eosinophil numbers are reduced with allergen 
avoidance. (Piacentini GL et a l , 1996; Lonnkvist K et al., 1999) These data 
suggest that direct measures of airway inflammation using selected sputum 
may be more useful than indirect measures in childhood 
asthma. 
.. Fig. 3.15 High quality cytospin slide for differential cell counts. 400 
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Fig. 3.16 Differential cell counts in cytoslide for eosinophil (1); 
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3.10 Conclusion 
In this chapter, we have reviewed methodology of HSCSI and protocol 
for sputum processing, staining and differential cell counts. 
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4.1 Introduction 
Asthma is characterized by variable airway obstruction, airway 
hyper-responsiveness and influx of inflammatory cells, especially eosinophils, 
into the bronchial mucosa. (Wardlaw AJ wt al., 2000) It is a common disease 
that can cause much morbidity and mortality. (Campbell MJ et al., 1997; 
Janson C et al., 1997; Dente FL et al., 2004) Management decisions in 
childhood asthma have traditionally been based on assessment of symptoms, 
results of peak expiratory flow rate (PEFR) or simple spirometry and the 
frequency of use of rescue medication. However, particular in mild childhood 
asthma, PEFR and spirometry have their limitations; as abnormal airway 
physiology is often absent. (Clancy K, 2004; Enright PL et al., 1994; Hunter CJ 
et al., 2002) In addition, these measurements do not correlate closely to the 
underlying eosinophilic airway inflammation, which is a predictor of asthmatic 
exacerbation and precursor of airway remodeling. (Crimi E et al., 1998) Up to 
80% of corticosteroid-naYve subjects (Green RH et al., 2002; Pizzichini E et al., 
1996; Silkoff PE et al., 2004) and more than 50% of corticosteroid treated 
‘ subjects (Pavord ID et al., 1997) with concurrent symptoms have sputum 
eosinophil counts outside the normal range yet their airway physiology may 
remain normal. Thus the monitoring of sputum eosinophil count may allow 
better asthma control and provide a useful guide in management. Recent 
evidence suggests that a treatment strategy directed at normalization of airway 
eosinophil count reduces asthma exacerbations and hospitalization. (Gibson PG 
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induction as a non-invasive method in assessing airway inflammation. (Louis R 
etal.,2000) 
The successful rate of sputum induction in children with asthma has been 
reported to vary from 68 — 100%. (Gibson PG et al., 2000) In young children 
the procedure is limited by the poor spirometric technique and low tidal volume 
that can be generated by the subject, and that limits the dose of saline delivered. 
(Riedler J., et al., 1994) In most study series utilizing sputum induction, the 
procedure is well tolerated but side effects including cough, bronchospasm, 
vomiting and anxiety have been reported. (Pizzichini E et al., 2002; Covar RA 
et al., 2004; Rytila P et al., 2004) It will therefore be clinically useful to have 
predictors that are associated with successful sputum induction so that children 
unlikely to produce an adequate sputum sample are not subjected to such 
procedure. In this study, we aimed to find out predictive factors for successful 
sputum induction in children with stable asthma. 
I 
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4.2 Methods 
4.2.1. Patient selection 
All children with stable asthma attending the Paediatric Chest Clinic of the 
Prince of Wales Hospital between the period October 2003 and December 2004 
were recruited. The ages of the children were between 6 and 18 years and all 
were able to cooperate with the tests. The diagnosis of asthma was made on 
standard grounds. (Warner JO, 1992) In addition, we defined stable asthmatics 
as those with (i) no asthmatic exacerbation for the preceding 4 weeks 
necessitating oral prednisolone or an increased use of inhaled corticosteroids, 
(ii) the use of rescue treatment no more than three times a week, and (iii) no 
clinical indication for change in treatment medication. We excluded from our 
study children who had other concomitant non-asthmatic chronic airway 
diseases such as bronchiectasis; those who used any prescription or 
over-the-counter medication that may affect the course of asthma or its 
treatment (such as Traditional Chinese Medicines); and children who were 
currently involved in any other asthma treatment trial. We obtained approval 
for the study from the Ethics Committee of The Chinese University of Hong 
‘ Kong, and the children's parents or guardians gave written informed consent. 
4.2.2 Study design 
.. This was a prospective observational study. A detailed history was taken 
and thorough physical examination performed on each child. Weight and height 
were recorded using standardized equipments. The recruited subjects were 
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management. 
(1) Asthma severity by visual analogue score, a subjective score from 0 to 10 
(0 = asymptomatic, 10 = severe disabling asthma) was obtained from the 
subjects. Similar visual analogue score to assess patients' daytime and 
night-time cough severity (0 = no cough, 10 = severe disabling cough) and 
how asthma and cough were affecting the subjects' well being and daily 
activity were also asked. (O=poor quality and 1 O=good quality). 
(2) Skin prick test to five groups of aero-allergens (house dust mite, cat and 
dog dander, cockroaches, grass and tree pollens and mixed moulds) was 
done according to standard procedures, using purified allergen extracts. A 
child was considered atopic if he had at least one skin test result that 
showed an induration with a diameter of at least 2 mm greater than the 
negative (normal saline) control. 
(3) Measurement of exhaled nitric oxide (eNO) using a chemilumiscence 
analyzer (NOA280i, Sievers Instruments, Boulder, CO, USA), sensitive to 
NO from 1 ppb to 200 ppm and with a resolution of 1 ppb and accuracy of 
±1 ppb, according to the American Thoracic Society guidelines. The subject 
‘ were comfortably seated without nose clip, inhaled NO-free air from a 
reservoir and subsequently exhaled against a resistor. The flow rate was set 
at 50 ml/s. This on-line measurement was taken in triplicate and the average 
- recorded. 
(4) Spirometry (Spirolab II, MIR, Italy) using standard technique measuring 
forced expiratory volume in the first second (FEVi) and forced vital 
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age- and sex-matched reference values. (Ip MS et al., 2000) 
(5) Sputum Induction. Hypertonic saline (4.5% HS) was used and sputum 
induction carried out using the standard technique. (Smith CM & Anderson 
SD, 1990; Fahy JV et al., 2001) The test was only performed if the child's 
FEVl was at least 65% predicted. The procedure was explained to the child, 
who would rinse his or her mouth with water to clear debris and squamous 
epithelial cells. The best of three FEVi obtained from spirometry was used 
as the baseline value. A nose-clip was worn and the child began inhalation 
of 4.5% HS for a period of 30 s. Spirometry was repeated 1 minute after the 
inhalation period. If no sputum was obtained and FEVi was greater than 
80% of the baseline value, the test continued. The child would then 
continue inhalation of HS for periods of 1 min, 2 min, and then three 
periods of 4 min each. FEVi was repeated after each inhalation period. The 
child was encouraged to cough up any sputum after each dose of HS and the 
sputum was collected into a polypropylene tube. A record of any side 
effects experienced by the child undertaking the test was made at the end of 
each elapsed time period. The study concluded either when the child 
• developed troublesome symptoms, when lung function had dropped below 
80% of the baseline value, or if the child could not be persuaded to 
complete the whole inhalation procedure. If the child had a greater than 
... 20% fall in FEVi, 500 meg salbutamol were administered using a 
metered-dose inhaler and spacer, and recovery monitored. The sputum 
sample was processed within 4 hours. The sputum was poured into a Petri 
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0.1% Dithiothreitol (DTT) (Sigma Chemicals, Poole, UK) and Phosphate 
buffered saline (PBS), the cell suspension was aspirated until homogenized 
and subsequently filtered with a 48 mm nylon gauge. The cell suspension 
obtained was then centrifuged at 400G for 10 minutes. Cytospin samples 
were prepared and stained by May-Griunwald Giemsa stain prior to 
performing a differential cell count by an individual who was unaware of 
the clinical data of the subjects. Specimens containing squamous epithelial 
cells of less than 50% of the total inflammatory cell number were 
considered adequate, ie successful induction. At least 400 inflammatory 
cells were counted for each specimen. Eosinophil count was expressed as 
percentage of total cell count. 
4.2.3 Statistical analysis 
Descriptive statistics were used to summarize the baseline characteristics 
of the patients and the results were expressed as median with interquartile 
ranges. Potential predictors were first evaluated individually by chi-square test 
and Mann-Whitney test for association with successful sputum induction. 
• Predictors with p < 0.25 were then analyzed by multivariate logistic regression 
analysis, using a forward stepwise selection strategy. When two or more 
potential predictors were highly correlated, the predictor that was clinically 
.. important was selected for entry. P value of < 0.05 was considered significant. 
SPSS version 11.5 for Windows was utilized for all statistical analysis. 
I 
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4.3 Results 
One hundred and thirty subjects with stable asthma were recruited. The 
median age was 11 years [IQR: 5]. There were 93 boys and 37 girls. All 
subjects by definition were atopic and 120 of them (92.3%) had positive skin 
prick test to more than one aeroallergen. 67 patients (51.5%) were using 
inhaled corticosteroids and the median beclomethasone equivalent dosage was 
125 meg (range 50mcg - 500mcg, assuming budesonide has equal potency and 
fluticasone is twice as potent as beclomethasone). 55 patients (42.3%) were 
using long-acting beta agonists and 8 patients (6%) were taking a regular 
leukotriene receptor antagonist. Asthma was well controlled in all patients and 
the baseline asthma severity score was low with a median of 0.7. All except two 
of the subjects had normal percent predicted FEVi ( � 8 0 % ) . The two cases had 
moderate obstructive deficit demonstrated on spirometry, and their predicted 
FEVi were 63% and 57%. The median eNO was 48.95 ppb (range from 
4.8ppb - 190ppb). The demographic characteristics of the subjects are shown in 
Table 4.1. 
‘ Sputum induction was well tolerated by all subjects. Sore throat was the 
most common complaint after the procedure, occurring in 20 subjects (15%), 
followed by chest discomfort, affecting 8 subjects (6%). The procedure was 
‘ prematurely terminated in three cases, in two because of vomiting and in the 
remaining one because of the unpleasant taste of 4.5% HS. None of the subjects 
developed significant clinical bronchospasm during the procedure. 93 subjects 
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The severity of asthma assessed by spirometry, use of second line asthma 
medications (long-acting beta agonists and leukotriene receptor antagonist) and 
age were not associated with successful sputum induction. Using multivariate 
analysis, only eNO was found to be a significant predictor (p = 0.022 
Mann-Whitney U test) (Table 4.2). Area under receiver operator characteristics 
(ROC) curves showing sensitivity and 1-specificity was 0.634 (Table 4.3). 
Male Female Total 
Male: female 93 37 93:37 
Height 144.0 (30.5) 144.7 (22.5) 144.35 (26.5) 
Age, year 11 (5.0) 10(10.0) 11(5) 
FEVI 1.97 (1.3) 1.83 (0.8) 1.94 (1.2) 
o/oFEVl 92.27% (17%) 86.36% (16%) 90.28% (17%) 
eNO, ppb 50.1 (63.7) 47.8 (58.05) 48.95 (61.37) 
Child score (Asthma) 9.5(1.5) 9.6(1.3) 9.5(1.4) 
Severity of asthma score 0.7(1.9) 0.6 (3.0) 0.7 (2.0) 
Child score (Cough) 9.5 (2.0) 9.5 (2.0) 9.5 (2.0) 
‘ Day time cough score 0.3 (1.25) 0.3 (0.9) 0.3 (1.2) 
Night time cough score 0.3 (1.45) 0.2 (0.8) 0.3 (1.2) 
Table 4.1 Demographic characteristics of subjects — Median (IQR) 
I » 
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4.4 Discussion 
In this study involving children with stable asthma, we found that the 
procedure of sputum induction was well tolerated by all participants. Exhaled 
nitric oxide but not age, was a significant predictive factor for successful 
induction. 
It is important to objectively measure airway inflammation as this can play 
a crucial part in the diagnosis and management of asthma in children and adults 
alike. Inhaled corticosteroids are the treatment of choice for eosinophilic 
airway inflammation. By assessing the degree of airway inflammation and 
targeting treatment in relation to response, we could prevent children from 
being exposed to unnecessarily high doses of inhaled corticosteroids and as a 
result suffer from their potential side effects. (Drake AJ et al., 2002) In this 
context, sputum induction provides a well-tolerated, safe and non-invasive 
method for the examination of the extent of airway inflammation in asthmatic 
patients. (Gibson PG et al., 2000 & Covar RA et al., 2004) Among various 
cellular and fluid phase markers found in sputum, sputum eosinophilia is well 
• validated as a marker of airway inflammation. (Gibson PG et al., 2000) Cai et 
al. have established the reference range of sputum eosinophil count for both 
normal and asthmatic children: the upper limit normal was found to be 2.5%. 
(Cai Y et al., 1998) Sputum eosinophil counts have also been found to have 
good correlation with asthma severity. (Gibson PG et al., 2000 & Louis R et al., 
2000) Green et al found that higher levels of sputum eosinophils correlated 
with greater airway obstruction and that the increase in sputum eosinophils can 
I » 
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be considered as a predictor for asthma exacerbations. (Green RH et al., 2002) 
In the same study, the authors found that the extent of control of airway 
inflammation and asthma exacerbation was better in the sputum management 
group, which targeted at normalizing airway eosinophilia, than in the traditional 
symptom based management group. There is accumulating evidence to suggest 
that sputum examination is a reliable and clinically useful method in the 
management of asthma, and this data is also extending to the paediatric 
population. (Gibson PG et al., 2000; Louis R et al , 2000; Covar RA et al., 2004; 
Lex C et al., 2005) 
Our success rate in obtaining an adequate sputum sample is in the range of 
70 to 80% which is similar to that reported in the literature and reiterates the 
feasibility of this procedure in children with asthma. (Gibson PG et al., 2000) 
Tolerability of the procedure has also been demonstrated in children with 
severe asthma. (Lex C et al., 2005) Although significant adverse effects 
associated with sputum induction were rare, the procedure can be unpleasant. 
Furthermore complications such as bronchospasm, vomiting, sore throat and 
• chest discomfort have all been reported. (Pizzichini E et al., 2002; Covar RA et 
al., 2004; Lex C et al., 2005) In our current study, the procedure was terminated 
prematurely on three occasions (2.3%). Fifteen percent of our subjects 
complained of sore throat and up to six percent had chest discomfort after the 
procedure. In the study by Lex et al, seven of 38 children complained of 
dyspnoea and/or wheeze during the induction and five (13%) had to terminate 
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have clinical parameters associated with successful induction so that children 
who do not satisfy such criteria are not subjected to the procedure. In the study 
by Lex et al” sputum induction was successful in 28 out of 38 children (74%) 
with difficult asthma. 50% of those less than 12 years of age were able to 
produce an adequate sample, compared to 88% of those who were older than 12 
years (Fisher's exact test, P=0.02). (Lex C et al., 2005) The authors suggested 
that age was an important predictor for successful sputum induction. By 
comparison, in our experience, the success of sputum induction instead appears 
to depend on the enthusiasm of the technician, degree of participation and 
cooperation and understanding of the procedure by the children involved. 
Although sputum induction in younger children often requires more 
demonstrations and explanations than older children, we did not find age to be 
an important predictive factor for success. Recently, a group reported success 
rate of 67% in obtaining adequate sputum on induction in children aged 5 years. 
(Rytila Pet al., 2004) 
Exhaled nitric oxide was found to be a significant predictor for successful 
‘ sputum induction in the current study. It has been reported that the magnitude 
of eNO was increased in proportion to bronchial wall inflammation or 
induced-sputum eosinophilia as well as to airway hyperresponsiveness. (Gibson 
.. PG et al., 2000; Fahy JV et al., 2001; Covar RA et al., 2004; Lex C et al., 2005,) 
The raised eNO may simply reflect an actively inflamed airway that is 
edematous and packed with numerous inflammatory cells and cytokines. With 
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it easier for us to obtain a sputum sample. It would be interesting to investigate 
whether sputum is as likely to be induced in the same subject once the 
underlying airway inflammation has been better controlled, i.e. reduced eNO 
levels. In a study involving children with mild asthma, the success rate for 
sputum induction fell from 82% to 68% after the initiation of inhaled 
corticosteroids. (Rytila P et al., 2004) It was observed in the study by Lex et al. 
that 33 out of 38 children had elevated eNO (> 23ppb) and of the 33 children, 
28 were successful in sputum induction to produce an adequate sample.'^ If we 
had used a cut-off of 23 ppb, 73 out of 98 children would have had a successful 
induction. The corresponding sensitivity, specificity, positive predictive and 
negative predictive values were 75.3%, 24.2%, 74.5% and 25.0% respectively. 
Despite acceptable sensitivity, the low specificity and negative predictive value 
would limit the clinical usefulness of this eNO cutoff value. 
There are certain limitations to our study. Firstly, the present study did not 
involve subjects with severe asthma. All except two of our study subjects had 
normal percent predicted FEVi at baseline. We therefore are not in a position to 
• comment on the applicability of our results to patients with severe asthma. 
However, in our clinical practice, severe asthma constitutes only a small 
proportion of our asthma workload and most patients belong to the category of 
... asthma subgroup similar to our study population. Therefore, the result 
generated from this study is still applicable to our daily practice. Secondly, as 
the area under ROC curve was too small, we were unable to establish a reliable 
cutoff with acceptable sensitivity and specificity. Larger sample size would be 
I 
85 
Chapter 4 Factors predicting successful sputum induction 
needed to derive more accurate results. Lastly, we did not include patients with 
other respiratory diseases such as chronic cough, bronchiectasis, or pulmonary 
tuberculosis. The predictive factors for sputum induction in different conditions 
might be different. 
Mann-Whitney U Wilcoxon W Z Asynip. Sig. (2-tailed) 
AGE 1421.000 1982.000 -.966 0.334 
HEIGHT 1398.500 丨 959.500 -1.081 0.280 
FEVI 1246.500 1807.500 -1.894 0.058 
FVC 1252.000 1813.000 -1.864 0.062 
FEVI - Predicted 1400.500 1961.500 -1.070 0.285 
FVC - Predicted 1386.500 1947.500 -1.145 0.252 
o/oFEVl 1287.000 1848.000 -1.677 0.094 
% FVC 1232.000 1793.000 -1.971 0.049 
FEVI /FVC 1571.000 6324.000 -.158 0.875 
eNO 1172.500 5925.500 -2.290 0.022* 
Child Score (Asthma) 1552.000 6305.000 -.262 0.793 
Asthma Severity Score 1586.000 6339.000 -.078 0.938 
Child Score (Cough) 1433.000 6186.000 -.907 0.364 
Table 4.2 Mann-Whitney Test Result 
( > 
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1.00-1 1" 




c^ 0.001 , , , 
0.00 .25 .50 .75 1.00 
1 - Specificity 
ENO (ppb) Sensitivity Specificity Positive Negative 
predictive value predictive value 
10 93.8% 9.1% 75.2% 33.3% 
15 86.6% 12.1% 74.1% 22.2% 
20 77.3% 21.2% 74.3% 24.1% 
. 23 75.3% 24.2% 74.5% 25.0% 
40 55.7% 33.3% 71.1% 20.4% 
60 36.1% 45.5% 66.0% 19.5% 
Table 4.3 Area under Receiver operator characteristics (ROC) Curves for eNO in 
predicting successful sputum induction 
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4.5 Conclusion 
In this study, we have demonstrated that sputum induction was feasible in 
children with asthma and a success rate of around 80% was reported. The 
majority of our patients tolerated the induction process well and no significant 
adverse effects were documented during the procedure. We have also identified 
exhaled nitric oxide, not age as a predictive factor for successful sputum 
induction. This could be clinically relevant to practicing clinicians who use this 
technique in their management of asthma, so that children unlikely to produce 
an adequate sample are not subjected to this procedure. However, more studies 
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Chapter 5 Use of once-daily fluticasone propionate in children with stable asthma -
study on airway inflammatory markers 
5.1 Introduction 
Asthma is primarily an inflammatory disorder of the airways and the most 
appropriate clinical management is to focus on preventing or alleviating the 
inflammation. Inhaled corticosteroids are effective treatment since they reduce 
airway inflammation, decrease bronchial hyper-reactivity and improve the 
long-term prognosis of asthma. (Haahtela T et al., 1991; Geddes DM, 1992) 
But ineffective asthma management resulting from poor adherence to 
prescribed treatment is common, and non-compliance rates have been reported 
to range from 30 to 70%. (Mawhinney H et al., 1991; Bender B et al., 1997; 
Apter AJ et al., 1998) A low rate of adherence to inhaled corticosteroid use is 
associated with more frequent asthma exacerbations in children. (Milgrom H et 
al., 1996) A simplified treatment plan that includes fewer medication 
administrations per day may improve adherence (Tashkin DP, 1995) and an 
attractive regimen is the use of once-daily medication. 
• Fluticasone propionate (FP) is a potent inhaled corticosteroid with 
negligible oral systemic bioavailability due to incomplete absorption and rapid 
first-pass metabolism. (Harding SM, 1990) It has also been shown to have high 
lipophilicity and affinity for the glucocorticoid receptor, a prolonged absorption 
phase, and an increased uptake and retention in the lungs. (Hogger P & 
Rohdewald P, 1994; Derendorf H et al., 1998) A human in vivo study 




Chapter 5 Once-daily fluticasone propionate in asthmatic children 
in peripheral lung tissues compared with serum. (Esmailpour N et al., 1997) 
These properties, which help in maintaining asthma control at low doses while 
minimizing systemic effects, are ideal for reducing the dose frequency. But the 
results of trials assessing the efficacy of once-daily FP have been mixed. (Ayres 
JG et al., 1995; Boulet LP et al, 2000; LaForce CF et al., 2000; Nathan RA et 
al., 2000; Wolfe J et al., 2000; ZuWallack R et al., 2000; Berger WE et al., 
2002) 
Results from an 8-week, double-blind trial involving 328 children with 
stable, mild-to-moderate asthma demonstrated that once-daily dose of lOOmcg 
FP powder administered via accuhaler in the evening was as effective as a 
twice-daily dose of 50mcg. (Hodges I & Netherway T, 2005) The main 
outcome measures in this study were asthma exacerbation and lung function. 
Whether improvements in these parameters translate to reduction in airway 
inflammation is unknown. In two studies involving children (LaForce CF et al., 
2000; ZuWallack R et al., 2000), twice-daily dosing of FP was found to provide 
significantly greater improvement in forced expiratory volume in the first 
‘ second (FEVi), reduction in the frequency of bronchodilator usage, and fewer 
subjects withdrew due to lack of efficacy when compared to the once-daily 
dosing. A recent review article concluded that once-daily administration of FP 
... is not currently recommended. (Purucker ME et al., 2003) 
> 
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In this study, we assessed whether in patients with stable asthma, 
once-daily FP was as effective as twice-daily in the control of airway 
inflammation as assessed by exhaled nitric oxide (eNO) and eosinophil count in 
induced sputum. We hypothesized that the once-daily regimen had similar 
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5.2 Methods 
5.2.1 Patient selection 
All children with stable asthma requiring twice-daily use of inhaled FP for 
3 months immediately prior to the study were recruited from the Paediatric 
Chest Clinic of the Prince of Wales Hospital. The age of the children was 
between 7 and 18 years and all were able to cooperate with the tests. The 
diagnosis of asthma was made on standard grounds. (American Thoracic 
Society, 1987) We defined stable asthma as no asthmatic exacerbation for the 
preceding 4 weeks necessitating oral prednisolone or an increased use of 
inhaled corticosteroids, the use of rescue treatment no more than three times a 
week, and with no clinical indication for change in treatment medication. 
Children who had other concomitant non-asthmatic chronic airway diseases 
such as bronchiectasis; those who used any prescription or over-the-counter 
medication which might have affected the course of asthma or its treatment; 
and children who were currently involved in any other asthma treatment trial 
were excluded. We had obtained approval for the study from the Ethics 
Committee of the Chinese University of Hong Kong, and written informed 
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5.2.2 Study design 
This was a prospective observational study. The recruited subjects were 
required to attend an asthma education session organized by a specialist asthma 
nurse before the start of the study. During the session, correct use of inhalers 
was checked and recording in the asthma diary was taught. The subjects were 
then entered into a run-in period that lasted for two weeks with continuous 
diary card recordings in the last 7 days. Criteria for acceptable asthma stability 
during the last 7 days of the run-in period included no more than 3 days of 
more than 3 times use of bronchodilator medication per day and no more than 
one night with awakenings resulting from asthma that required treatment with 
bronchodilator. 
The two-week run-in period was to confirm adequate asthma control on 
the current dosage of FP and it was followed by 8 weeks when the subjects 
were given the same dosage of FP to be taken once-daily in the evening (for 
example, FP 125 micrograms twice daily was changed to FP 250 micrograms 
daily). The same inhaler device was used. The subjects were given rescue 
• medication for use as required, in the form of metered dose inhaler ventolin 
with or without a spacer. No other bronchodilator or anti-inflammatory 
medications were permitted during the study. Nasal corticosteroids and 
antihistamines were allowed if required. The subjects were then required to 
return for repeat assessment after 8 weeks of once-daily FP. The following 
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Visit 1 
Baseline measurement 
, Flixotide medication is changed from Twice daily to Once daily with identical dosage ^ 
i.e. 125mg twice daily will become 250mg once daily at night \ , 
1  
6 - 8 weeks 
J L .  
Visit 2 
Repeat all measurements 
Fig. 5.1 Study Plan 
(1) Patients had to keep daily diary cards and to record use of FP, use of 
bronchodilator, daytime and night-time asthma symptoms (cough, wheeze) 
and sleep disturbance. Asthma severity by visual analogue score, a 
subjective score from 0 to 10 (0 = asymptomatic, 10 = severe disabling 
asthma) was obtained at the start and end of the study (start = after the 
run-in period, end = 8 weeks after the subjects had been on once- daily FP) 
from the patients. Similar visual analogue scores to assess (a) patients' 
• preference of dosing regimen (0 = least preferred, 10 = most preferred), and 
(b) patients' daytime and nighttime cough severity (0 = no cough, 10 = 
severe disabling cough) were also obtained from the subjects. 
... (2) eNO was measured by a rapid-response chemiluminescent method using 
the Sievers 280i NOA analyzer (Sievers，Boulder, CO, USA), with 
sensitivity from 1 ppb to 200 ppm, and a resolution of 1 ppb and accuracy 
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(American Thoracic Society, 1999) The subject were comfortably seated 
without nose clip, inhaled NO-free air from a reservoir and subsequently 
exhaled against a resistor. The flow rate was set at 50 ml/s. This on-line 
measurement was taken in triplicate and the average recorded. 
(3) Spirometry (Spirolab II, MIR, Italy) using standard technique measuring 
FEVl and forced vital capacity (FVC). The obtained best of three efforts 
was compared with local age- and sex-matched reference values. (Ip MS et 
al., 2000) 
(4) Sputum induction. 4.5% hypertonic saline (HS) was used and sputum 
induction carried out using the standard technique. (Smith CM & Anderson 
SD, 1999 & Fahy JV et al., 2001) The test was only performed if the child's 
FEVl was at least 65% predicted. The procedure was explained to the child, 
who would rinse his or her mouth with water to clear debris and squamous 
epithelial cells. The best of three FEVi obtained from spirometry was used 
as the baseline value. A nose-clip was worn and the child began inhalation 
of HS for a period of 30 s. Spirometry was repeated 1 minute after the 
inhalation period. If no sputum was obtained and FEVi was greater than 
• 80% of the baseline value, the test continued. The child would then 
continue inhalation of HS for periods of 1 min, 2 min, and then three 
periods of 4 min each. FEVi was repeated after each inhalation period. The 
child was encouraged to cough up any sputum after each dose of HS and 
the sputum was collected into a polypropylene tube. A record of any side 
effects experienced by the child undertaking the test was made at the end of 
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developed troublesome symptoms, when lung function had dropped below 
80% of the baseline value, or if the child could not be persuaded to 
complete the whole inhalation procedure. If the child had a greater than 
20% fall in FEVi, 500 meg salbutamol were administered using a 
metered-dose inhaler and spacer, and recovery monitored. The sputum 
sample was processed within 4 hours. The sputum was poured into a Petri 
dish and the viscid mucocellular portions selected. After treatment with 
0.1% Dithiothreitol (DTT) (Sigma Chemicals, Poole, UK) and Phosphate 
buffered saline (PBS), the cell suspension was aspirated until homogenized 
and subsequently filtered with a 48 |am nylon gauge. The cell suspension 
obtained was then centrifuged at 400G for 10 minutes. Cytospin samples 
were prepared and stained by May-Griunwald Giemsa stain prior to 
performing a differential cell count by an individual who was unaware of 
the clinical data of the subjects. Specimens containing squamous epithelial 
cells of less than 50% of the total inflammatory cell number were 
considered adequate. At least 400 inflammatory cells were counted for each 
specimen. Eosinophil count was expressed as percentage of total cell count. 
5.2.3 Statistical analysis 
Descriptive statistics were used to summarize the baseline characteristics 
of the patients and the results were expressed as median (IQR). Wilcoxon test 
was used for comparing paired data and p < 0.05 was considered as statistically 
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5.3 Results 
Thirty subjects with stable asthma were recruited but one failed to return 
for his second assessment and he was excluded from the final analysis. There 
were 18 boys and 11 girls. The median age was 10 years (IQR: 3.5). The 
dosage of FP ranged from 100 micrograms to 500 micrograms per day and 
none of the subjects were taking any other anti-inflammatory drugs for their 
asthma. The demographic characteristics of the subjects, results of their 
spirometry, eNO, percentage sputum eosinophil count and visual analogue 
scores at baseline and after 8 weeks of once-daily FP are shown in Table 1. 
Sputum induction was well tolerated by all subjects and no adverse effects were 
reported. Twenty-three subjects (79%) were able to produce an adequate 
sputum sample on the first visit and eighteen of them on both visits. Asthma 
was well controlled in all patients and the baseline asthma severity score was 
low (median 1.0). All except two of the subjects had normal percent predicted 
FEVi ( � 8 0 % ) , the two cases had moderate obstructive deficit demonstrated on 
spirometry, and their percent predicted FEVi were 63% and 57% respectively. 
• None of the subjects reported worsening of their asthma during the 
8-weeks study period. There was a statistically significant improvement in eNO 
[40.5 ppb (58.5) vs. 33.9 ppb (34.8), p = 0.023], and sputum eosinophil count 
[4.25% (10.25%) vs. 1.00% (2.6%), p = 0.023] after the medication was 
changed to once-daily use. There was also a trend of improved asthma severity 
assessed by the visual analogue score after 8 weeks of once-daily FP [1.0 (3.5) 
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=0.347, night-time cough scores, p = 0.351 and daytime cough scores, p = 
0.843 after treatment was changed to once-daily FP. 
All subjects preferred the once-daily dosing regimen and the median 
preference score was 10 (p = 0.033). All visual analogues scores before and 
after treatment change were summarized in Table 5.1 and fig. 5.2 - 5.5. 
At baseline after run-in After 8 weeks of once-daily FP 
Age (years) 10(3.5) 
Height (cm) 141 (21.5) 
FEVi (% predicted) 88.49% (16.1%) 90.50% (21.2%) 
FVC (% predicted) 90.02% (18.1%) 89.84% (16.9%) 
FEVi / FVC 91.85% (9.9%) 97.11% (16.6%) 
eNO (ppb) 40.5 (58.5) 33.9 (34.8) 
Sputum Eos (%) 4.25% (10.25%) 1 % (2.6%) 
Asthma severity 1.0 (3.5) 0(1.5) 
Night time cough 0 (0) 0 (0) 
Day time cough 0(1.0) 0(1.0) 
Preference score 10 (4.5) 10 (0.5) 
Table 5.1 Demographic characteristics, spirometry, inflammatory markers and 
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Fig. 5.2 Visual analogue score - Severity of Asthma 
Severity of Asthma 
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Fig. 5.4 Visual analogue score - Day Time Cough 
Day Time Cough 
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Fig. 5.5 Visual analogue score - Night Time Cough 
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5.4 Discussion 
In this study we were able to demonstrate that the use of once-daily FP 
was at least as effective as twice-daily dosing in the control of airway 
inflammation in a cohort of children with stable asthma. There was significant 
improvement in the airway inflammatory markers after the medication was 
changed to once-daily use. This dosage frequency was also the preferred 
regimen by the subjects. 
Fluticasone propionate (FP) is a potent inhaled corticosteroid with 
negligible oral systemic bioavailability. (Harding SM, 1990) It has high 
lipophilicity and affinity for the glucocorticoid receptors allowing prolonged 
retention in lung tissues. (Derendorf H et al., 1998; Hogger P & Rohdewald P, 
1994) These properties make the drug an ideal candidate for reducing the dose 
frequency. However, in a recent review which included two paediatric studies, 
it was concluded that once-daily administration of FP is not currently 
recommended. (Purucker ME et al., 2003) The authors of the review article had 
found that twice-daily dosing was superior to once-daily dosing at the same 
‘ nominal dose in change from baseline in the pre-dose FEVi. There are major 
differences in study design between published trials and our current study. In 
the former, the subjects with persistent asthma were randomized to receive 
either once-daily or twice-daily dosing of FP and in many cases, the subjects 
had either been on inhaled corticosteroids of another class or they were 
steroid-naive. In our study, subjects had been on twice-daily FP for at least 3 
months and they all underwent a dose frequency reduction to once-daily while 
f » 
101 
Chapter 5 Once-daily fluticasone propionate in asthmatic children 
maintaining the same nominal dose. We looked at markers of airway 
inflammation as our primary outcome measure, unlike published studies where 
pre-dose FEVi or peak expiratory flow rate (PEFR) were their main outcome 
parameters. We decided that airway inflammation would provide more 
important information in relation to disease control, clinical management and 
prognosis. It has been shown that eosinophilic airway inflammation is a reliable 
predictor of asthmatic exacerbation and a precursor of airway remodeling. 
(Crimi E et al., 1998) Recent evidence also suggests that a treatment strategy 
directed at normalization of airway eosinophil count reduces asthma 
exacerbations and hospital admissions. (Gibson PG et al., 2000) We were able 
to demonstrate significant reduction in sputum eosinophil count and exhaled 
nitric oxide after the treatment was changed to once-daily use. This will have 
important long-term implications in relation to disease control and prognosis. 
The use of once-daily inhaled corticosteroids offers convenience and 
improved acceptability to the patient. This was also the view expressed by our 
study subjects and all of whom preferred the once-daily regimen. It is possible 
‘ that once daily treatment resulted in better medication compliance and hence 
improvement in disease control. This is especially important in the 
management of childhood asthma as compliance rate has consistently been 
... demonstrated to be sub-optimal and a strong relationship has been established 
between poor compliance and risk of disease exacerbation. (Milgrom H et al., 
1996) The optimal time for once-daily administration of medication has not 
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medication in the evening as parents are more likely to be at home in the 
evening than in the morning, another measure to ensure parental supervision 
and medication compliance. Nevertheless the final decision will depend very 
much on the patient's preference and home circumstances. The issue of safety 
may be another concern as higher peak serum concentrations may conceivably 
surpass some critical "adverse event" threshold while maintaining an area 
under the curve (AUC) similar to that achieved by twice-daily dosing. 
Unpublished pharmacokinetic data from the US Food and Drug Administration 
however, suggest comparable systemic exposure (as measured by FP AUC 
concentrations) whether the same nominal dose of FP is given once-daily or 
divided into a twice-daily regimen. (Purucker ME et al., 2003) 
There are certain limitations to our study. Firstly, the present study did not 
involve subjects with severe asthma. All except two of our study subjects had 
normal percent predicted FEVi at baseline. We therefore are not in a position to 
comment on the feasibility of using once-daily corticosteroids in patients with 
severe asthma. In our clinical practice, severe asthma constitutes only a small 
• proportion of our asthma workload and most patients belong to the category of 
asthma subgroup similar to our study population. Therefore, the result 
generated from this study is still applicable to our daily practice. Besides, if 
once-daily use is associated with better medication compliance, that should be 
to the benefit of the patients regardless of their asthma severity. Secondly, the 
sample size was small as we only managed to recruit 29 subjects. We did not 
divide our subjects randomly into two groups comparing once-daily and 
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twice-daily use of medication concurrently. Our group of patients had mild 
asthma and they were well controlled on their initial dose of inhaled 
corticosteroids. We did not make an attempt to determine whether this was the 
lowest dose required. It is also possible that the improvement seen in the 
various parameters was a result of improved adherence with medications. 
Lastly, whether the use of once-daily regimen is also applicable to other classes 
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5.5 Conclusion 
The results of this study indicate that once-daily use of FP is equally 
effective as twice-daily treatment in maintaining asthma stability and reducing 
airway inflammation in children. These findings suggest that in children with 
stable asthma and well-controlled on inhaled fluticasone propionate, their 
treatment regimen can be changed from twice-daily to once-daily at the same 
nominal dose. At the end of the day, the best treatment for asthma is the one the 
patient would comply to once-daily treatment, being the preferred option, could 
result in better drug compliance, which could have favourable long-term effects 
on disease control and prognosis. 
# 
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Chapter 6 Assessment of cough frequency in children with stable asthma: study on 
airway inflammatory markers 
6.1 Introduction 
Cough is a very common symptom of respiratory diseases such as viral 
infection and asthma in children. It is audible and can interfere with sleep for 
both patients and their parents. Cough can also be the first warning symptom of 
serious underlying problems such as foreign body inhalation or acute 
exacerbation of asthma. Parents are therefore understandably anxious and often 
seek medical advice for their children's cough. (Chang AB, 1999) In one study, 
parents reported that lack of sleep and choking were their main concerns for 
their children's cough. (Fuller Pet al., 1998) 
In childhood asthma, cough can be the only dominant symptom. (Chang 
AB et al., 1997; Rietveld S & Rijssenbeek-Nouwens LH, 1998). In a South 
African study, only 2.2% of children with classical asthma wheeze but do not 
cough. (Green R & Luyt D, 1997) Cough is also a dominant feature in 
childhood asthma exacerbation. In an unselected group of children hospitalized 
‘ for an asthma exacerbation, almost 50% of parents reported that cough was 
usually or always present with an asthma exacerbation. (Chang AB et al., 1997) 
In a study involving children with moderate to severe asthma, Li AM et al, 
were able to find increased cough frequency in their subjects compared to 
normal controls. They also demonstrated a positive correlation between cough 
frequency and exhaled nitric oxide, a marker of underlying eosinophilic airway 
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asthma is also increased and whether a correlation still exists between cough 
and airway inflammation is unknown. 
Problems and difficulties have been encountered by researchers in 
quantifying clinically relevant cough. Subjective recording of cough by means 
of diary cards and patient's report of cough frequency can be very variable and 
its reliability has been questioned (Archer LN & Simpson H, 1985; Thompson 
AH et al., 1987; Hoskyns EW et AL, 1991; Brunekreef B et al., 1992; Falconer 
A et al., 1993; Juniper EF et al , 1994; Pirila P & Sovijarvi ARA, 1995; Chang 
AB et al., 1998; Hamutcu R et al., 2002) Previous investigators have used 
conventional tape recorders to quantify cough objectively (Pirila P & Sovijarvi 
ARA, 1995; Falconer A et al., 1993). However, tape recorders are bulky and 
the lack of portability precludes their use in daytime cough assessments during 
normal activity. In addition, they rely only on a single audio signal. An 
audiovisual method for recording nocturnal cough has been successfully used in 
environments not suitable for sound only recording. (Picciotto A et al., 1998) 
Audiovisual recording allows accurate identification of the timing and number 
‘ of cough episodes of the patient at night; however, this method is not practical 
during the day because it limits normal activity. Recently the use of an 
ambulatory cough monitoring device (LR 100) has been validated in both 
adults and children. (Munyard P et al., 1994; Hamutcu R et al., 2002) This is a 
portable, multi-parametric recording device, worn in a waist bag, and 
connected to the chest with three electromyographic (EMG) leads and a 




Chapter 6 Assessment of cough frequency in children 
effects during recording were reported. (Munyard P et al., 1996; Corrigan DL & 
Paton JY, 2003; Li AM et al , 2003; ZihlifN et al., 2005) 
In this study, we aimed to (1) measure the cough frequency in children 
with stable asthma using a validated objective cough monitoring device, and (2) 
assess the correlation between the measured cough frequency with the degree 
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6.2 Cough Monitoring Machine LR 102 
6.2.1 General Description 
The LR102 cough recorder is an optimised ambulatory cough recording 
system. A simplified block diagram of the LR102 ambulatory cough recording 
system is shown in the following figure. 
W 
- 厂 phono 
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Fig. 6.1 LR102 ambulatory cough recording system 
The LR102 cough recording system pre-processes the raw phono and EMG 
signals to provide a representative signal for cough. Both phono and EMG 
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A combination of analogue and digital processing are used under the control 
of a dedicated set of microprocessors, which control acquisition and memory card 
recording. 
The LR102 cough recorder has a built-in accelerometer, which allows the 
mean activity of the wearer, i.e. the patient, to be recorded at the same time. A pH 
channel is provided so that oesophageal reflux episodes could also be determined 
and correlated with the cough attacks. However, we did not use this function of 
the monitor in our study. 
6.2.2 Real time communication with cough recorder 
LR 102 cough recorder allows real time communication between the patient 
and the software so that the recording of the cough signals can be seen by the 
patient and the technician simultaneously. Therefore a baseline measurement and 
the position of the ECG leads and the Phono can be adjusted during installation. 
This will ensure correct position of the body leads and adequate signal pick-up 
before actual recording starts. 
6.2.3 Placement of ECG electrode 
The skin of the patient should be thoroughly cleaned to remove any grease. 
A distance between EMG electrodes A and B governs the sensitivity and, 
therefore, size of the tracing obtained. The patient should be asked to cough to 
establish a base line EMG response. The LED level indicator for EMG should 
light up when the cough machine is recording. If the LED is on all the time it 
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usually indicates that one of the electrodes has become detached. 
6.2.4 Phono Sensor Placement 
The phono sensor should be placed just off the midline of the body. The skin 
of the patient should be thoroughly cleaned to remove any grease and moisture. 
Double-sided adhesive rings should be used for attaching the Phono sensor to the 
skin. 
6.2.5 Analysing Cough Data 
LR 102 can automatically filter the "noise" in the data. Typical thresholds are 
set at trigger level = 50% and blanking period = 2 seconds or greater. On 
completion, the data will appear marked with green vertical tag bars where a 
cough has appeared within 1 second of the tag bar placement. Cough is identified 
by two signals: the surface EMG from the muscles of active expiration, and a 
filtered audio signal. A valid cough maneuver is defined as the presence of both 
signals. The EMG signal processing is such that voluntary muscle movement is 
filtered out, and the rapidly recruited abdominal wall muscles involved in 
‘ coughing are recorded. Simultaneously the audio signal of the cough is 
recorded, thus giving two signals from which to verify that the child has 
coughed. The recording obtained will be played back, and displayed 
simultaneously visually on a personal computer. The recorded data were 
analyzed automatically and reviewed visually. Visual inspection confirmed that 
all cough epochs identified automatically were genuine. Coughing events were 
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cluster (cough epoch) as a close succession of cough spikes (<2 sec between 
individual coughs) recorded by each trigger of the recorder. The cough data 
were expressed as total numbers of cough episodes (individual spike cough 
cluster) per recording time. 
The installation of the whole set-up procedure takes about 15 minutes and 
the subject is then allowed to go home with the monitor and to return the next 
day for removal of the monitor. 
6.2.6 Protocol for installation of cough machine 
1. Clean the skin with Alcohol Prep Pad to remove any grease. 
2. Stick the EMG electrodes according to the above figure (make sure the 
electrode is still moist) 
3. Connect the EMG cable to the electrodes (Green to the bottom, red to 
the left and black to the right) 
4. Place the Phono sensor just off the midline as indicated in figure and 
stick with double-sided adhesive ring. 
‘ 5. Secure the attachment and position of the electrode with micropore. 
6. Connect the Phono Sensor and EMG cable to the cough machine. 
7. Insert the batteries and fill in the record sheet. 
8. Real-time communication with the Cough Recorder and the PC 
9. Choose Com 2 as the communication port 
10. Plug in the serial communication cable, which has been connected to 
the Com port, to the serial port on the cough machine. 
> 
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11. Insert the MMC card to switch on the cough machine. 
12. Press "Zero blanking memory card" to blank the card. 
13. Press "Monitor", then the recorder start to monitor real-time signal. 
14. The patient is asked to perform baseline measurement. 
15. Press "Stop Monitor" after the baseline measurement. 
16. Detach the cable, secure the door and the patient are free to go. 
17. When the patient returns, detach the cough machine, ECG leads and 
MMC card. The MMC card has recorded the data and will be used for 
analysis. 
6.2.7 Cough Data Analysis 
1. Insert the MMC card into the 4 in 1 adaptor and insert the adaptor in 
Omni Driver 
2. Press "Import" — Enter the code — Press "Import" 
3. Real time data will appear on screen on completion. 
4. Press "Auto Tag" + "Set Tags" 
5. On completion, all signals are screened and those unlikely cough 
• signals are removed in accordance to the baseline. 
6. The numbers of cough per hours are recorded and a histogram is 
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6.3 Methods 
6.3.1 Subjects 
Children with stable asthma between 7 - 1 8 years of age were invited to 
participate in the study. All children were first examined by a physician and 
patients suffering from upper respiratory tract infection were excluded. We 
defined stable asthma as no asthmatic exacerbation for the preceding 4 weeks 
necessitating oral prednisolone or an increased use of inhaled corticosteroids, 
the use of rescue treatment no more than three times a week, and with no 
clinical indication for change in treatment medication. All children were 
recruited from attendants to the paediatric chest clinic held at the Prince of 
Wales Hospital. Informed consent was obtained from all subjects and their 
parents. 
6.3.2 Study design 
A detailed history was taken and thorough physical examination 
performed on each child. Weight and height were recorded using standardized 
equipments. The participants underwent the following assessments: 
‘ (1) Asthma severity by visual analogue score, a subjective score from 0 to 10 
(0 = asymptomatic, 10 = severe disabling asthma) was obtained from the 
subjects. Similar visual analogue score to assess patients' daytime and 
’. night-time cough severity (0 = no cough, 10 = severe disabling cough), and 
(b) surrogate quality of life score — asthma and cough (0二poor quality and 
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(2) Skin prick test 
Five groups of aero-allergens (house dust mite, cat and dog dander, 
cockroaches, grass and tree pollens and mixed moulds) were done 
according to standard procedures, using purified allergen extracts. A child 
is considered atopic if he has at least one skin test result that shows 
indurations with a diameter of at least 3mm greater than the negative 
(normal saline) control. 
(3) Exhaled nitric oxide (eNO) measurement 
Exhaled nitric oxide (eNO) was measured by a rapid-response 
chemiluminescent method using the Sievers 280i NOA analyzer (Sievers, 
Boulder, CO, USA), with sensitivity from 1 ppb to 200 ppm, and a 
resolution of 1 ppb and accuracy of 士 1 ppb, according to the American 
Thoracic Society guidelines. (American Thoracic Society, 1987). The 
subject were comfortably seated without nose clip, inhaled NO-free air 
from a reservoir and subsequently exhaled against a resistor. The flow rate 
was set at 50 ml/s. This on-line measurement was taken in triplicate and 
• the average recorded. 
(4) Spirometry 
Spirometry (Spirolab II, MIR, Italy) using standard technique 
measuring FEVi and forced vital capacity (FVC). The obtained best of 
three efforts was compared with local age- and sex-matched reference 
values. (IpMS et al., 2000) 
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(5) Sputum induction 
Sputum induction. 4.5% hypertonic saline (HS) was used. The test 
was only performed if the child's FEVi was at least 65% predicted. The 
procedure was explained to the child, who would rinse his or her mouth 
with water to clear debris and squamous epithelial cells. The best of three 
FEVi obtained from spirometry was used as the baseline value. A 
nose-clip was worn and the child began inhalation of HS for a period of 
30 s. Spirometry was repeated 1 minute after the inhalation period. If no 
sputum was obtained and FEVi was greater than 80% of the baseline value, 
the test continued. The child would then continue inhalation of HS for 
periods of 1 min, 2 min, and then three periods of 4 min each. FEVi was 
repeated after each inhalation period. The child was encouraged to cough 
up any sputum after each dose of HS and the sputum was collected into a 
polypropylene tube. A record of any side effects experienced by the child 
undertaking the test was made at the end of each elapsed time period. The 
study concluded either when the child developed troublesome symptoms, 
when lung function had dropped below 80% of the baseline value, or if the 
• child could not be persuaded to complete the whole inhalation procedure. 
If the child had a greater than 20% fall in FEVi, 500 meg salbutamol were 
administered using a metered-dose inhaler and spacer, and recovery 
... monitored. The sputum sample was processed within 4 hours. The sputum 
was poured into a Petri dish and the viscid mucocellular portions selected. 
After treatment with 0.1% Dithiothreitol (DTT) (Sigma Chemicals, Poole, 
UK) and Phosphate buffered saline (PBS), the cell suspension was 
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aspirated until homogenized and subsequently filtered with a 48 mm nylon 
gauge. The cell suspension obtained was then centrifuged at 400G for 10 
minutes. Cytospin samples were prepared and stained by May-Griunwald 
Giemsa stain prior to performing a differential cell count and counted by a 
technician who was blinded to the clinical data of the subjects. Specimens 
containing squamous epithelial cells of less than 50% of the total 
inflammatory cell number were considered adequate. At least 400 
inflammatory cells were counted for each specimen. Eosinophil count was 
expressed as percentage of total cell count. 
(6) Cough monitoring 
The LR 102 cough recorder was used in this study. The procedure of 
the operation has been described. The cough recorder allowed 24 hours 
recording. Once the cough recorder has been installed, the subjects and 
their parents were asked to complete a time activity recording sheet which 
included time the subject went to bed and woke up. All subjects returned 




Chapter 6 Assessment of cough frequency in children 
6.3.3 Statistical analysis 
The data will be presented as median with interquartile range (IQR). 
Spearman's rank correlation coefficient was used to assess the association 
between the various parameters. SPSS for Windows statistical software 
(Release 11.0, SPSS Inc., Chicago, Illinois) was used in the analyses. The 
level of significance was set at 5% in all comparisons, and all statistical 
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6.4 Results 
Thirty Six children (aged 7 - 1 7 years) with mean ages 11.68 years (IQR: 
9—14) were recruited in this study. There were 24 boys and 12 girls. All 
subjects by definition were atopic and the commonest allergen was house dust 
mite. Eleven of them (31 %) had more than one allergen sensitivity and all of 
them (100%) had sensitivity to house dust mite. Five patients were using 
inhaled corticosteroids and the range of beclomethasone equivalent dosage was 
between 50mcg and 250mcg, (assuming budesonide has equal potency and 
fluticasone is twice as potent as beclomethasone). The remaining 31 patients 
were using short-acting beta agonist on an as required basis. Therefore, by 
definition, all subjects had mild intermittent or persistent asthma. (National 
Asthma Education and Prevention Program Expert Panel Report 2，1997) 
Cough recording was successful in all children and 25 out of 36 children 
(69.4%) produced adequate sputum sample at induction. No adverse events or 
sleep disturbance were reported. The median number of cough episodes over a 
24 hour period was found to be 25.5 (IQR 16 - 42.8) and this was significantly 
. greater than that reported for normal children; 11 cough episodes per day 
(p<0.001) (Munyard P & Bush A., 1996) (Table 6.1) 
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Mean Median IQR: 25 IQR: 75 
Age / yrs 11.68 11.50 9.00 14.00 
Height / cm 148.86 149.10 136.75 161.25 
Weight / kg 40.70 36.70 30.80 47.50 
Number of cough 
32.36 25.50 16.00 42.75 
episodes recorded 
eNO/ppb 65.74 56.05 37.38 105.00 
% predicted FEVl 89.3% 83.3% 81.1% 97.6% 
% predicted FVC 93.3% 84.0% 91.1% 100.0% 
% Eosinophil 6.34 1.75 0.50 5.13 
% Neutrophil 19.07 8.25 6.13 18.25 
Quality of Life score- 8.75 9.70 8.00 10.00 
Asthma 
Severity of asthma 1.27 0.30 0.00 2.00 
score 
Quality of Life score- 8.21 9.35 7.00 10.00 
Cough 
Day Time Cough 1.11 0.20 0.00 1.18 
Night Time Cough 1.20 0.20 0.00 1.78 
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It was found that the number of cough episodes correlated positively 
with the percentage of neutrophils (p<0.005) in sputum. eNO was found to 
correlate with the percentage of sputum eosinophils (p=0.01). We were not 
able to demonstrate any significant correlation between symptom scores, 
lung function parameters with the number of cough episodes detected. 
(Table 6.2) 
Correlation Coefficient P value 
eNO - 0.185 0.279 
FEVI - 0.215 0.208 
FVC -0.119 0.491 
% Eosinophil 0.02 0.924 
% Neutrophil 0.833 0.000* 
Quality of Life score- 0.096 0.606 
Asthma 
Severity of ^sthma score - 0.077 0.679 
Quality of Life score- - 0.100 0.592 
Cough 
Day Time Cough - 0.090 0.630 
Night Time Cough - 0.068 0.717 
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Fig. 6.2 Cough frequency distribution 
The nighttime cough and daytime cough frequency were compared. We 
were not able to measure sleep stage, so we asked all patients and their parents 
to report the time when the patients slept and woke up in the morning. We 
• found that all subjects slept at between 2200 — 2400 and woke up between 
0700 - 0900. So we arbitrarily defined night cough as cough occurring between 
2300 and 0700 hours and daytime cough as cough occurring at any other time. 
We calculated the hourly cough frequency for these two periods. Median 
daytime coughs / hours were significantly greater than nighttime coughs (71.5 / 
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6.5 Discussions 
In this study, our aims were to assess the cough frequency in a group of 
children with stable mild asthma and to examine the relationship between the 
measured cough frequencies with airway inflammation. We were able to show, 
despite recruited at a time of apparent stability, that our cohort of mild 
asthmatics had increased cough frequency compared to normal children. 
(Munyard P & Bush A., 1996) The cough frequency was also found to correlate 
with percentage sputum neutrophil count. 
We did not find any correlation between the subjective; self reported 
quality of life cough score (p = 0.592), daytime cough score (p = 0.630) and 
nighttime cough score (p = 0.717) with the actual cough frequency recorded. 
This finding is similar to what has been reported in the literature, questioning 
the reliability of subjective reported cough symptom. (Archer LN & Simpson H, 
1985; Hoskyns EW et AL., 1991; Falconer A et al., 1993; Chang AB et al., 
1998; Hamutcu Ret al., 2002). 
‘ We have always believed that children with asthma would cough 
significantly more often than control subjects during exacerbations, but not 
during remission. (Rietveld S & Rijssenbeek-Nouwens L H., 1998) This is in 
contrast to the findings of our study where we found that children with stable 
asthma had an increased cough frequency compared with data previously 
obtained from normal school children. (Munyard P & Bush A., 1996) Similar to 
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the authors also reported greater cough frequency compared to normal controls. 
In addition, we have found that cough frequency is greater during the day than 
at night, despite conventional teaching on the importance of night cough in 
asthma. 
Persistent airway inflammation in stable asthmatics may explain our 
finding of increased total cough. A recent study showed that persistent airway 
inflammation was still evident in asthmatics that had been asymptomatic with 
normal lung function, (van den Toorn LM et al., 2001) On-going airway 
inflammation in our group of stable asthmatics may be supported by the finding 
that the median sputum eosinophil count was 1.75% (IR 0.5 - 5.13), compared 
to the values reported for normal controls which were 0.3% (IR 0.1 - 1.05) 
(Gibson PG et al., 2001). Although a direct relationship between cough 
frequency and sputum eosinophilia could not be demonstrated, we found a 
significant correlation between increased cough with the percentage sputum 
neutrophil count. Our findings are inconsistent with previous studies in cough 
and airway inflammation. Chang et al (Chang AB et al., 2002) found that 
• increase in cough and eosinophilic inflammation were the characteristic of mild 
asthma exacerbation with insignificant change in lung function. Li et al. in their 
study of thirty-two (Li AM et al., 2003) children with stable moderate to severe 
asthma showed that the cough frequency was related to eNO. We were unable 
to explain the positive correlation between cough frequency and sputum 
neutrophilia. Previous investigators have reported the known causes of cough 
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limitation associated with cigarette smoking, (Pizzichini E et al., 1996; 
Keatings VM et al., 1997; Stanescu D et al., 1996) pollutants such as ozone 
(Fahy JV et al , 1995; Vagaggini B et al., 1999; Holz O et al., 1999), endotoxin 
(Nightingale JA et al., 1998) and viral infection (Pizzichini MM et al., 1998). 
We did not obtain detailed information from our patients in relation to possible 
exposure to the above but none of subjects smoke. In fact, the median sputum 
neutrophil count from our cohort was 8.25% (IR 6.13 - 18.25) which was not 
elevated compared to what has been reported for normal controls; 35% (IR 12 -
88) (Gibson Am J Respir Crit Care Med 2001) Therefore this correlation may 
be a chance finding rather than a genuine relationship. 
There are several limitations in our studies. Firstly, we recruited only 36 
patients, whether an increased sample size would have given a significant 
correlation between cough frequency and other parameters especially sputum 
eosinophil count, is not known. We did not have normal Chinese children to 
serve as comparison to our cohort of patients for cough frequency. But we 
could not envisage race as an important determining factor in cough frequency. 
• Secondly, we could not assess sleep stage or even whether the child was asleep. 
We relied mainly on the information provided by the parents. Thirdly, this study 
was a cross sectional study at a specific time point. We did not attempt to assess 
whether the current medications taken by the patients were optimal or not. 
Longitudinal studies to determine whether increasing asthma treatment or the 
use of anti-neutrophilic measures are useful strategy to treat increased cough 
should be carried out. The main strength of this study was the use of objective 
I » 
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cough monitor relying on two signals to confirm genuine coughing by the child. 
Sound quality may be affected by the sleep position of the patient and the 
actual recordings may be contaminated by sounds made by people nearby. By 
utilizing two signals to confirm an episode of cough greatly improved 
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6.6 Conclusions 
In summary, we were able to demonstrate increased cough frequency in 
children with mild asthma despite their disease being in remission. The increased 
cough might be driven by a neutrophilic inflammatory pathway, the significance of 
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Chapter 7 Summary and conclusion 
Traditionally, assessment of asthma in children relies heavily on clinical history. 
Objective measurement by spirometry, PEFR, eNO, test of atopy by SKT have been used 
in assessing severity of asthma and predicting asthma exacerbations but they lack 
sensitivity and good correlation to underlying airway inflammation. BAL and bronchial 
biopsy are direct method in assessing airway inflammation. However, their use in clinical 
practice and especially in children is limited because of their invasive nature. Hypertonic 
saline challenge and sputum induction (HSCSI) is an important assessment method, 
especially in children. The combined procedure allows assessment of airway 
hyperresponsiveness and airway inflammation at the same time and it is non-invasive, 
safe and relatively well tolerated by all. In chapter 2, methods in assessing paediatric 
asthma, airway hyperresponsiveness and airway inflammation as well as various research 
studies conducted in relation to assessing the airway inflammation in persistence asthma, 
evaluating the efficacy of inhaled corticosteroids in reducing sputum eosinophilia, 
distinguishing eosinophilic asthma from non-eosinophilic asthma were reviewed. 
In chapter 3, the protocol and the laboratory setup of HSCSI, at the Prince of Wales 
Hospital and other technical considerations such as data interpretation and safety aspects 
have been reviewed and evaluated. Besides, the protocol of sputum induction, processing 
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In Chapter 4, eNO was identified as a predictor associated with successful sputum 
induction; however, a cutoff point with satisfactory sensitivity and specificity was unable 
to be defined likely related to our small sample size and the heterogenous nature of the 
study population. Further research into this particular aspect of sputum induction would 
be clinically relevant to practicing clinicians who use this technique in their management 
of asthmatic patients, so that children unlikely to produce an adequate sample are not 
subjected to the procedure. 
In chapter 5, sputum induction was used to evaluate the efficacy of once-daily 
inhaled corticosteroids (fluticasone proprionate) in maintaining asthma stability. It was 
found that once-daily dosage was equally effective in reducing airway inflammation in 
children. The findings suggest that in children with stable asthma and well-controlled on 
inhaled fluticasone propionate, their treatment regimen can be changed from twice-daily 
to once-daily at the same nominal dose. This study has demonstrated the use of sputum 
induction as a non-invasive maker in assessing severity of asthma and highlights the 
concept of targeting airway inflammation instead of symptoms in asthma management. 
At the end of the day, the best treatment for asthma is the one the patient would comply 
• to. Once-daily treatment, being the preferred option by most children in our study, could 
result in better drug compliance, which could have favorable long-term effects on disease 
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In chapter 6, a study with the use of the recently available cough monitoring 
machine LR102 and sputum induction in children was carried out. We were able to 
demonstrate that stable asthmatics had increased cough frequency compared to normal 
controls. The cough frequency was also found to be positively correlated with the degree 
of neutrophilic airway inflammation. 
In conclusion, combined hypertonic saline challenges and sputum induction is safe 
and well tolerated among children. It has its clinical value as a non-invasive assessment 
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Future direction: 
Combined HSCSI is now generally accepted as a research tool only as the procedure 
is time consuming and labour intensive; however, it may find its way into routine clinical 
practice in the future. Combined HSCSI may have its clinical value in three time scales. 
The first is the single timepoint application of the procedure in the diagnosis of airway 
disease. The second is the repeated use of the procedure in monitoring airway 
inflammation and response to treatment. The third refers to its potential in predicting 
outcome of the underlying airway disease. 
A number of components in the fluid phase (supernatant) of sputum have been 
shown to be reproducible and sensitive treatment markers of asthma. However, 
difficulties in standardization, lack of normal control data and the problem associated 
with salivary contamination have led to their limited use in clinical studies. More 
research into the use of markers present within the sputum supernatant is definitely 
required to verify their clinical application. 
In the future, more research work will be needed to provide a clinically friendly 
‘ sputum induction procedure so that it can be performed routinely and cost-effectively in 
clinical practice. It is our hope that the procedure will one day be automated and the 
whole process can be completed within an acceptable time frame so that it can be made 
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te^ The Chinese University of Hong Kong 
Department of Paediatrics - Pulmonary Function Assessment 
I. Skin Prick Test (Visit 1 only) ^ ^ 
1. Histamine mm 7. Penicillium mm ^ ^ 
P L A C E L > B ^ HERE 
2. Saline mm 8. Mould mm ^ ^ 
. 9. Pollen ^ ^ 
3. D. Pteronyssinus mm 阳⑴ 
4. D. Farinae mm ⑴^咖！^⑴ Date: • A s t hma ( N C M G ) 
~ “ Asthma (CMG) 
5. Amer. Cockroach mm 11. Dog mm Visit; —— 
6. Ger. Cockroach mm 12. Cat mm Plione: . 
II. eNO Measurement (Sievers NOA) Smoking: ACT IVE / PASSIVE / NIL 
Data: 1. 2. 3. 4. 
Procedure: Done / Failed No of trial ； eNO: 。/。dev: 
IV. Hypertonic Saline Challenge Rinse mouth; Yes 
Nebuliser cup: (pre-weight) g … . . . , . , ,  
Asthma medication and time last taken: 
Nebuliser cup : (post-weight) g  
Difference in weight: g . 
Cumulative time ： ^ Time FEV I Change in % Sputum Remarks — 
Output (g/min): Baseline % ^  
i ase l i ne Measurement (FEV1/FVC): Best 0.5 min % ^  
Predicted : / “ 1 min % ^  
"ist trial: / 厂 min % ^  
I n d trial: I ' 4 min % 糊 
3rd trial: / 4 min % ^  
4th trial: . I 4 min % ^  
5th trial: I I post % 观 
FEV I 20% fall: Result; Sputum Induced / Saliva only / No Sputum 
(Best FEV I X 0.8) 卜 
V. Simple Spirometry 
^ Predicted Observed % predicted Post Observed % Predicted 
FEV1: _ — - FEV1: 
F ^ 一 FVC  
7ev i/ fvc 一 I ~ | fev i/ fvc — 
Remarks / Side Effects reported : 
I » 
國 The Chinese University of Hong Kong 
起 ; D e p a r t m e n t of Paediatrics - Questionnaire   
Date: Visit no:  
1. Asthma Score I I I I | I I I 
0 “ ~ ~ ^ 
Bad Good 
2. Severity of Asthma | | | | I I I I I 
^ ~ ~ ~ ~ ~ ~ ” ~ ” W 
Mild Severe 
3. Convenience score | | | | | | | | | 
• 0 5 “ ~ ^ 
Extremely Extremely 
Inconvenience • Convenience 
4. Cough Score | | | | | I I I I I I  
^ ~ ~ ” ~ ~ ” “ “ ~ ~ 10 
Bad Good 
5. Day Time Cough | | | | | | I I I I I I  
^ “ ~ ~ ~ ” ~ ~ " " " \0 
No Cough Severe 
6. Night Time Cough | | | | | | | | | | | | I I I 
0 ~ ~ 5 ~ I T 
No Cough Severe 
( 
) • 
Remarks I Chest Examinations: 
I. Macroscopic Examination and Cell counting (Choose the best one)  
Est. Volume: ml Re-suspension volume (1ml — 10^/ml cell)  
Color: opague / green / yellow / jelly TCC x Post filtration volume  
Sputum used:  
Comment: Saliva only / Poor but acceptable / Good = 
Sample I : Alive: Dead: Viability = % 
TCC = Total cell count in 5 squares 15 x 0.02 x 10®/ml TCC x 9 = x 10^/ml  
=( )15 X 0 . 0 2 = X 1 0 6 / m l I I I . C y t o s l i d e ( m i n i m u m 2 s l ides , m a x i m u m 4 s l i des ) 
Sample 2 : Alive: Dead: Code:  
TCC = Total cell count in 5 squares 15 x 0.02 x 10® /ml IV. Supernatant  
T{ ) /5 X 0.02 = X 10®/ml Code: | 
II. Cytoslide Quality Slide no:  
1. Debris  
2. Cell Outline  
3. Nuclear Morphology  
4. Squamous . 
5. Overall impression  
6. Slide Macrophage present  
7. No of cells on slide  
Total Score  
III. Differential Cell counting Slide no:  
1. Neutrophils  
2. Eosinophils  
3. Macrophages  
4. Lymphocytes  
5. Col. Epithelial cell . 
6. Squamous 
Date of Installation: Time: Baseline measurement: Phono EMG 
Date of Return: Time: 1. Deep cough  
1. Cough machine with door secure screw 2. Speaking  
2. Waist bag and batteries (4AA) 3. Deep Breathe  
3. MMC card, Phono sensor and EMG leads 4. Laughing  
Patient: Checked by: ^  
6. 
Cough data: (no of tags) 
一—1 I 2 I 3 I 4 I 5 I 6 I 7 I 8 I 9 I 10 I 11 I 12 
13 14 15 16 — 17 18 "“"“19 20 21 22 23 24 — 
Start; (press 3 consecutive signals) 
End: (press 3 consecutive signals) 
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